



# 2025 INTERIM REPORT



**LifeTech Scientific Corporation**  
**先 健 科 技 公 司**

(Incorporated in the Cayman Islands with limited liability)

**Stock Code: 01302**

# CONTENTS

<b>2</b>	<b>Corporate Information</b>
<b>4</b>	<b>Financial Highlights</b>
<b>5</b>	<b>Management Discussion and Analysis</b>
<b>20</b>	<b>Corporate Governance Highlights</b>
<b>22</b>	<b>Other Information</b>
<b>39</b>	<b>Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income</b>
<b>40</b>	<b>Condensed Consolidated Statement of Financial Position</b>
<b>42</b>	<b>Condensed Consolidated Statement of Changes in Equity</b>
<b>43</b>	<b>Condensed Consolidated Statement of Cash Flows</b>
<b>44</b>	<b>Notes to the Condensed Consolidated Financial Statements</b>

# CORPORATE INFORMATION

As at 29 August 2025

## EXECUTIVE DIRECTORS

XIE Yuehui

*(Chairman and Chief Executive Officer)*

LIU Jianxiong

*(Executive Vice President, Chief Financial Officer  
and Company Secretary)*

RUAN Xingmei

*(Chief Compliance Officer)*

## NON-EXECUTIVE DIRECTOR

JIANG Feng

## INDEPENDENT NON-EXECUTIVE DIRECTORS

LIANG Hsien Tse Joseph

WANG Wansong

ZHOU Luming

## COMPANY SECRETARY

LIU Jianxiong

## AUTHORISED REPRESENTATIVES

XIE Yuehui

LIU Jianxiong

## AUDIT COMMITTEE

LIANG Hsien Tse Joseph *(Chairman)*

ZHOU Luming

WANG Wansong

## NOMINATION COMMITTEE

ZHOU Luming *(Chairman)*

XIE Yuehui

LIANG Hsien Tse Joseph

RUAN Xingmei (appointed on 23 May 2025)

WANG Wansong (appointed on 23 May 2025)

## REMUNERATION COMMITTEE

WANG Wansong *(Chairman)*

XIE Yuehui

LIANG Hsien Tse Joseph

## HONG KONG SHARE REGISTRAR

Tricor Investor Services Limited

17/F, Far East Finance Centre

16 Harcourt Road, Hong Kong

## WEBSITE

[www.lifetechmed.com](http://www.lifetechmed.com)

## STOCK CODE

1302

## LISTING DATE ON THE GROWTH ENTERPRISE MARKET

10 November 2011

## DATE OF TRANSFER OF LISTING FROM THE GROWTH ENTERPRISE MARKET TO THE MAIN BOARD

6 November 2013

## PRINCIPAL BANKERS

China Merchants Bank Co., Ltd.

Shenzhen Chegongmiao Branch

Block A, 1/F, Tianxiang Building

Chegongmiao Tianan Industrial District

Futian, Shenzhen, PRC

China Construction Bank Corporation, Qianhai Branch

Block B, Minsheng Internet Building, Qianhai

Shenzhen, PRC



**HONG KONG LEGAL ADVISER**

Allen Overy Shearman Sterling  
9/F, Three Exchange Square  
Central  
Hong Kong SAR

**AUDITOR**

Deloitte Touche Tohmatsu  
Registered Public Interest Entity Auditors  
35/F, One Pacific Place  
88 Queensway  
Hong Kong

**REGISTERED OFFICE IN CAYMAN ISLANDS**

PO Box 309  
Ugland House  
Grand Cayman, KY1-1104  
Cayman Islands

**PRINCIPAL PLACE OF BUSINESS  
AND ADDRESS OF HEADQUARTERS**

LifeTech Scientific Building  
No.22, Keji 12th Road South  
High-tech Industrial Park  
Nanshan District  
Shenzhen 518063, PRC

**PLACE OF BUSINESS IN HONG KONG  
REGISTERED UNDER PART 16 OF  
THE HONG KONG COMPANIES ORDINANCE**

31/F, 148 Electric Road  
North Point  
Hong Kong

**PRINCIPAL SHARE REGISTRAR  
AND TRANSFER OFFICE**

Maples Fund Services (Cayman) Limited  
PO Box 1093, Boundary Hall  
Cricket Square, Grand Cayman, KY1-1102  
Cayman Islands

# FINANCIAL HIGHLIGHTS

The board (the “Board”) of directors (the “Directors”, each a “Director”) of LifeTech Scientific Corporation (the “Company” or “Lifetech”) is pleased to announce the unaudited consolidated results of the Company and its subsidiaries (collectively the “Group”) for the six months ended 30 June 2025 (the “Reporting Period”) together with the comparative figures for the corresponding period of 2024.

Six months ended 30 June			
	2025 RMB'000 (Unaudited)	2024 RMB'000 (Unaudited)	Change
Revenue	676,707	652,831	3.7%
Gross profit	497,755	515,384	(3.4%)
Operating profit	64,387	202,006	(68.1%)
Profit for the period	41,765	185,808	(77.5%)
Profit for the period attributable to owners of the Company	55,074	205,557	(73.2%)
Earnings per share			
– Basic	RMB1.3 cents	RMB4.6 cents	(71.7%)
– Diluted	RMB1.3 cents	RMB4.6 cents	(71.7%)

  

	30 June 2025 RMB'000 (Unaudited)	31 December 2024 RMB'000 (Audited)	Change
<b>Assets</b>			
Non-current assets	2,760,395	2,566,205	7.6%
Current assets	2,573,290	2,334,173	10.2%
<b>Total assets</b>	<b>5,333,685</b>	<b>4,900,378</b>	<b>8.8%</b>
<b>Liabilities</b>			
Current liabilities	993,262	815,638	21.8%
Non-current liabilities	603,473	609,311	(1.0%)
<b>Total liabilities</b>	<b>1,596,735</b>	<b>1,424,949</b>	<b>12.1%</b>
<b>Total equity</b>	<b>3,736,950</b>	<b>3,475,429</b>	<b>7.5%</b>

# MANAGEMENT DISCUSSION AND ANALYSIS

## BUSINESS OVERVIEW

The Group is a developer, manufacturer and marketer of advanced minimally invasive interventional medical devices for cardiovascular, peripheral vascular diseases and disorders. We currently have three main product lines, covering the structural heart diseases business, the peripheral vascular diseases business and the cardiac pacing and electrophysiology business. Structural heart diseases related products mainly include the congenital heart diseases occluders and Left Atrial Appendage ("LAA") occluders; peripheral vascular diseases related products mainly include vena cava filters and stent grafts; and cardiac pacing and electrophysiology related products mainly include implantable cardiac pacemakers and cardiac pacing leads. These three product lines provide clinically effective and commercially attractive product offerings. The Group has built a strong sales network globally and has distributors in numerous countries across Asia, Europe, North America, South America and Africa.

## FIRST-HALF PERFORMANCE

The Group recorded a revenue of approximately RMB676.7 million for the six months ended 30 June 2025, representing an increase of approximately RMB23.9 million or approximately 3.7% as compared with the revenue of approximately RMB652.8 million for the corresponding period of 2024. China's mainland remained our largest market, where the revenue generated accounted for approximately 74.1% of our total revenue for the six months ended 30 June 2025 (corresponding period of 2024: approximately 75.1%). Meanwhile, Asia (excluding China's mainland) and Europe were our two largest overseas markets, which accounted for approximately 11.4% and 11.0%, respectively, of our total revenue for the six months ended 30 June 2025 (corresponding period of 2024: approximately 10.9% and 10.0%, respectively). Domestic sales of the Group increased by approximately 2.2% as compared with the corresponding period of 2024, while overseas sales of the Group increased by approximately 8.0% as compared with the corresponding period of 2024, which was mainly attributable to the Company's active expansion of overseas business and effective marketing strategies.

Net profit attributable to owners of the Company for the six months ended 30 June 2025, excluding certain non-recurring items as set out below, was approximately RMB238.5 million as compared with the net profit amounting to approximately RMB233.6 million for the six months ended 30 June 2024, representing an increase of approximately 2.1%. Such non-recurring items include (i) the other gains arising from financial assets at fair value through profit or loss ("FVTPL") of approximately RMB9.9 million for the six months ended 30 June 2025 (corresponding period of 2024: gains of approximately RMB32.9 million); and (ii) the share-based payment expenses of approximately RMB193.5 million for the six months ended 30 June 2025 (corresponding period of 2024: approximately RMB61.3 million). Taking into account the effects of such non-recurring items, the net profit attributable to owners of the Company for the six months ended 30 June 2025 was approximately RMB55.1 million, with a decrease of approximately 73.2% as compared with approximately RMB205.6 million for the six months ended 30 June 2024. The decrease was mainly due to the change in non-recurring items.

## MANAGEMENT DISCUSSION AND ANALYSIS

### SALES AND MARKETING

The Group has an experienced team of sales and marketing professionals that are dedicated to support and manage existing distribution networks and to explore new markets. We enhanced the brand awareness and influence of our products by organizing or participating in domestic and international medical conferences, academic activities, seminars, live broadcasts of surgical procedures and delivering trainings to medical professionals. Meanwhile, the Lifetech Knowledge Exchange Program connected cardiovascular experts around the world for academic exchanges. These experts exchanged valuable medical experience and clinical skills which were highly conducive to promoting the development of medical technology in the field of minimally invasive cardiovascular interventions. Such activities showcased our strengths in product innovation and helped enhance the Company's sales and influence in the international medical community.

### RESEARCH AND DEVELOPMENT ("R&D")

The Company's independently developed innovative domestic medical device products will maintain the competitive strength of the Company and also provide more effective treatments to patients around the world. In the first half of 2025, the Company continuously strengthened its innovation capabilities and accelerated the development of products, so as to maintain its industry leading position.

During the six months ended 30 June 2025, we have achieved the following milestones in the R&D field:

- Aortic Stent Graft System (consists of the Ankura™ Pro Aortic Stent Graft System and Longuette™ Aortic Branch Stent Graft System), Aortic Arch Stent Graft System (consists of the Ankura™ Plus Aortic Arch Stent Graft System and CSkirt™ Aortic Arch Branch Stent Graft System), Peripheral Balloon Dilatation Catheter (Large diameter), Yoscop™ Multi-loop Snare System and SteerEase™-m Introducer have obtained the National Medical Products Administration ("NMPA") certification;
- IrisFit™ PFO Occluder and SteerEase™ Introducer have obtained the CE MDR (Medical Device Regulation) certification. Such products have previously obtained the CE MDD (Medical Device Directive) certification;
- Thoracoabdominal Artery Stent Graft System (consists of the G-Branch™ Thoracoabdominal Aortic Stent Graft System, SilverFlow™ PV Peripheral Vascular Stent Graft System and Aortic Extension Stent Graft System) and Iliac Bifurcation Device (consists of the G-iliac™ Pro Iliac Bifurcation Stent Graft System and SilverFlow™ Pro Internal Iliac Stent Graft System), etc. are pending registration approval in China;
- Aortic Stent Graft System (consists of the Ankura™ Pro Aortic Stent Graft System and Longuette™ Aortic Branch Stent Graft System), Fitaya™ Vena Cava Filter System, Futhrough™ Stent Graft Balloon Catheter, Yuranos™ Abdominal Aortic Stent Graft System and G-iliac™ Iliac Bifurcation Device are pending registration approval of CE certification;
- Concave Supra-arch Branched Stent-Graft System, X-Clip™ Mitral Valve Clip System and Aortic Arch Single Branch Stent Graft System (consists of the Aortic Arch Stent Graft System and Aortic Branch Stent Graft System) are currently at the stage of pre-registration clinical enrollment in China;
- Cera™ PFO Occluder has completed pre-marketing clinical enrollment and is currently under clinical follow-up in China;

- IBS Titan™ Sirolimus-Eluting Iron Bioresorbable Peripheral Scaffold System is currently at the stage of clinical enrollment in China and in Europe, and its CE registration application has been submitted; and
- IBS™ Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System has successfully completed the five-year follow-up of the phase I clinical study and the two-year follow-up of the phase II and III clinical study, further confirming its safety and efficacy. Additionally, its CE and NMPA registration application have been submitted.

### INTELLECTUAL PROPERTY RIGHTS

Intellectual property is an important intangible asset of the Group and also an internal driving force to improve our core competitiveness in the medical device market. During the six months ended 30 June 2025, the Group has filed 73 patent applications and separately, 41 patents were successfully registered. As at 30 June 2025, the Group has filed a total of 2,464 valid patent applications, of which 1,123 patents were registered and valid.

### FINANCIAL REVIEW

#### OVERVIEW

The following discussion is based on, and should be read in conjunction with, the financial information and the notes appended thereto included in this interim report.

#### REVENUE

The revenue of the Group was approximately RMB676.7 million for the six months ended 30 June 2025, with an increase of approximately RMB23.9 million or approximately 3.7% as compared with the revenue of approximately RMB652.8 million for the corresponding period of 2024. The increase was mainly due to the increase of revenue from sales of stent grafts and LAA occluders.

#### *Revenue from the structural heart diseases business*

The turnover contributed by the structural heart diseases business for the six months ended 30 June 2025 was approximately RMB271.5 million (corresponding period of 2024: approximately RMB271.2 million), representing an increase of approximately 0.1% as compared with the corresponding period of 2024.

We have diversified our product portfolio to cover a wide spectrum of the structural heart diseases business, including but not limited to, LAA occluders and three generations of congenital heart diseases occluders namely HeartR, Cera and CeraFlex. As compared with the corresponding period of 2024, the revenue generated from the sales of LAA occluders increased by approximately 14.7%, while congenital heart diseases occluders decreased by approximately 7.2%.



## MANAGEMENT DISCUSSION AND ANALYSIS

### *Revenue from the peripheral vascular diseases business*

The turnover contributed by the peripheral vascular diseases business for the six months ended 30 June 2025 was approximately RMB391.7 million (corresponding period of 2024: approximately RMB380.7 million), representing an increase of approximately 2.9% as compared with the corresponding period of 2024.

The products offered in the peripheral vascular diseases business mainly include vena cava filters, Thoracic Aortic Aneurysm stent grafts, Abdominal Aortic Aneurysm stent grafts, Iliac Artery Bifurcation stent grafts, Aortic stent graft systems and Aortic Arch stent graft systems. As compared with the corresponding period of 2024, the revenue generated from the sales of stent grafts increased by approximately 9.6%, while the revenue generated from the sales of vena cava filters decreased by approximately 16.8%.

### *Revenue from the cardiac pacing and electrophysiology business*

The turnover contributed by the cardiac pacing and electrophysiology business for the six months ended 30 June 2025 was approximately RMB13.5 million (corresponding period of 2024: approximately RMB0.9 million), representing an increase of approximately 1,400.0% as compared with the corresponding period of 2024.

## GROSS PROFIT AND GROSS PROFIT MARGIN

Gross profit of the Group decreased by approximately 3.4% from approximately RMB515.4 million for the six months ended 30 June 2024 to approximately RMB497.8 million for the six months ended 30 June 2025.

Gross profit margin decreased 5.3 percentage points from approximately 78.9% for the six months ended 30 June 2024 to approximately 73.6% for the six months ended 30 June 2025. The decrease was mainly due to: (i) the decrease in the unit selling price of certain products in specific regions resulting from the impact of the centralised procurement policy; and (ii) the change in sales portfolios.

## OTHER INCOME, EXPENSES, GAINS AND LOSSES

Other income, expenses, gains and losses increased from approximately RMB49.1 million for the six months ended 30 June 2024 to approximately RMB50.4 million for the six months ended 30 June 2025. The slight change was mainly due to (i) the increase in net foreign exchange gains; and (ii) the decrease in the gains from changes in fair value of financial assets at FVTPL. The above two factors were offset by each other and resulted in an overall minimal impact.

## FINANCIAL ASSETS AT FVTPL

On 25 May 2018, the Group invested USD6.0 million (equivalent to approximately RMB38.2 million) to subscribe for the partnership interest of approximately 9.69% in Ally Bridge Group Innovation Capital Partners III, L.P., a private equity fund established in the Cayman Islands (the "2018 Equity Fund"). The 2018 Equity Fund principally invests in securities or assets of companies in the healthcare industry, with a particular focus on cross-border innovative late-stage venture opportunities and crossover investments. The fair value of our investment in the 2018 Equity Fund as at 30 June 2025 amounted to approximately RMB9.2 million (31 December 2024: approximately RMB8.9 million), representing approximately 0.2% (31 December 2024: approximately 0.2%) of the Company's total assets. Based on the cumulative net distributions of approximately RMB57.8 million by the fund to the Group, coupled with the outlook of the healthcare industry, the Company is optimistic on the prospects of its investments in the 2018 Equity Fund.

On 8 January 2021, the Group invested RMB10.0 million to subscribe for a hybrid fund unit ("2021 Hybrid Fund"). The fair value of this investment as at 30 June 2025 amounted to approximately RMB13.5 million (31 December 2024: approximately RMB12.5 million), representing approximately 0.3% (31 December 2024: approximately 0.3%) of the Company's total assets.

On 24 October 2022, the Group entered into a subscription agreement with certain independent third parties pursuant to which the Group agreed to subscribe in Ally Bridge Group Global Life Science Capital Partners V, L.P. (the "2022 Equity Fund"), as a limited partner, for an aggregate consideration of USD20.0 million (equivalent to approximately RMB144.4 million) in cash. The purposes of the 2022 Equity Fund are to seek capital appreciation primarily by acquiring, holding and disposing of securities, independently or with others, primarily in non-listed or, sometimes, listed entities involved in the healthcare industry, with a particular focus on leading innovative technologies. The fair value of our investment in the 2022 Equity Fund as at 30 June 2025 amounted to approximately RMB196.1 million (31 December 2024: approximately RMB200.5 million), representing approximately 3.7% (31 December 2024: approximately 4.1%) of the Company's total assets.

On 28 November 2023, the Group invested RMB50.0 million to subscribe for a hybrid fund unit ("2023 Hybrid Fund"). The fair value of this investment as at 30 June 2025 amounted to approximately RMB43.2 million (31 December 2024: approximately RMB30.2 million), representing approximately 0.8% (31 December 2024: approximately 0.6%) of the Company's total assets.

The aggregate unrealised foreign exchange losses in financial assets at FVTPL was approximately RMB0.9 million for the six months ended 30 June 2025 (corresponding period of 2024: gains of approximately RMB0.9 million), and the aggregate gains from changes in fair value of financial assets at FVTPL was approximately RMB10.7 million (corresponding period of 2024: gains of approximately RMB31.9 million).

The investments are classified as financial assets at FVTPL in accordance with IFRS 9. In the opinion of the Directors, the above investments are held for long-term strategic investment purposes and, as such, the above investments are classified as non-current assets.

## SELLING AND DISTRIBUTION EXPENSES

Selling and distribution expenses increased by approximately 67.3% from approximately RMB150.0 million for the six months ended 30 June 2024 to approximately RMB250.9 million for the six months ended 30 June 2025. The increase was mainly due to the increase in staff costs, of which the increase in share-based payment expenses amounted to approximately RMB128.4 million for the six months ended 30 June 2025 (corresponding period of 2024: approximately RMB24.1 million).

## ADMINISTRATION EXPENSES

Administration expenses increased by approximately 63.1% from approximately RMB72.6 million for the six months ended 30 June 2024 to approximately RMB118.4 million for the six months ended 30 June 2025. This increase was mainly due to the increase in staff costs, of which the increase in share-based payment expenses amounted to approximately RMB54.6 million for the six months ended 30 June 2025 (corresponding period of 2024: approximately RMB16.0 million).

## MANAGEMENT DISCUSSION AND ANALYSIS

### R&D EXPENSES

R&D expenses decreased by approximately 18.2% from approximately RMB139.9 million for the six months ended 30 June 2024 to approximately RMB114.5 million for the six months ended 30 June 2025. In addition, during the current period, approximately RMB41.5 million (corresponding period of 2024: approximately RMB64.3 million) was capitalised as development expenditure. Taking into account of such capitalised expenditure, R&D costs decreased by approximately 23.6% from approximately RMB204.2 million for the six months ended 30 June 2024 to approximately RMB156.0 million for the six months ended 30 June 2025. This decrease was mainly due to a reduction related to Biotyx Medical (Shenzhen) Co., Ltd. (元心科技(深圳)有限公司) ("Biotyx Medical") in share-based payment expenses, which was approximately RMB5.9 million for the the six months ended 30 June 2025 (corresponding period of 2024: approximately RMB36.3 million).

### OPERATING PROFIT

During the six months ended 30 June 2025, the Group recorded an operating profit of approximately RMB64.4 million, which represented a decrease of approximately 68.1% as compared with the operating profit of approximately RMB202.0 million for the corresponding period of 2024. The decrease was mainly due to (i) increase in staff costs resulting from the increase in the share-based payment expenses; and (ii) decrease in the gains from changes in fair value of financial assets at FVTPL.

### SHARE OF RESULTS IN ASSOCIATES

The Group's share of results in associates was approximately RMB5.3 million for the six months ended 30 June 2025 (corresponding period of 2024: losses of approximately RMB1.4 million).

### FINANCE INCOME AND FINANCE COSTS

Finance income increased by approximately 15.7% from approximately RMB8.9 million for the six months ended 30 June 2024 to approximately RMB10.3 million for the six months ended 30 June 2025.

Finance costs decreased by approximately 88.9% from approximately RMB0.9 million for the six months ended 30 June 2024 to approximately RMB0.1 million for the six months ended 30 June 2025.

### FINANCIAL LIABILITIES AT FVTPL

In 2020, Lifetech Scientific (Shenzhen) Co., Ltd. (先健科技(深圳)有限公司) ("Lifetech Shenzhen"), a wholly owned subsidiary of the Company, entered into a shareholders' agreement ("Series A Agreement") with certain independent third parties, and in 2023 entered into another shareholders' agreement ("Series B Agreement") with certain independent third parties, for issuance of shares of Biotyx Medical. Pursuant to the above mentioned Series A and Series B Agreements, if Biotyx Medical is unable to meet certain specified conditions under agreed timeframe, some holders of these shares will have the right to require Biotyx Medical to redeem all of their shares at the predetermined consideration. Accordingly, such shares are classified as a financial liability.

The fair value change in relation to the financial liabilities for the six months ended 30 June 2025 is insignificant.

The fair value of financial liabilities at FVTPL as at 30 June 2025 amounted to approximately RMB558.3 million (31 December 2024: approximately RMB558.3 million).

Additional information is set out in Note 19 to the condensed consolidated financial statements in this interim report.

## INCOME TAX

Income tax increased from approximately RMB22.8 million for the six months ended 30 June 2024 to approximately RMB38.0 million for the six months ended 30 June 2025, which was mainly due to increased assessable income.

## NET PROFIT

Net profit attributable to owners of the Company for the six months ended 30 June 2025, excluding certain non-recurring items as set out below, was approximately RMB238.5 million as compared with the net profit amounting to approximately RMB233.6 million for the six months ended 30 June 2024, representing an increase of approximately 2.1%. Such non-recurring items include (i) the other gains arising from financial assets at FVTPL of approximately RMB9.9 million for the six months ended 30 June 2025 (corresponding period of 2024: gains of approximately RMB32.9 million); and (ii) the share-based payment expenses of approximately RMB193.5 million for the six months ended 30 June 2025 (corresponding period of 2024: approximately RMB61.3 million). Taking into account the effects of such non-recurring items, the net profit attributable to owners of the Company for the six months ended 30 June 2025 was approximately RMB55.1 million, with a decrease of approximately 73.2% as compared with approximately RMB205.6 million for the six months ended 30 June 2024. The decrease was mainly due to the change in non-recurring items.

## EQUITY INSTRUMENTS AT FAIR VALUE THROUGH OTHER COMPREHENSIVE INCOME ("FVTOCI")

On 21 September 2022, the Group entered into a subscription agreement with Jenscare Scientific Co., Ltd. (寧波健世科技股份有限公司) ("Jenscare Scientific") pursuant to which the Group agreed to subscribe for shares of Jenscare Scientific upon its initial public offering, as a cornerstone investor, for an aggregate consideration of USD20.0 million (equivalent to approximately RMB143.9 million) in cash with the price of HKD27.8 per share. The fair value of the equity security in the listed entity is determined based on the closing prices quoted in active markets. They are accounted for using their fair values based on quoted market prices. The fair value of this investment as at 30 June 2025 amounted to approximately RMB43.4 million (31 December 2024: approximately RMB17.1 million), representing approximately 0.8% of the Company's total assets (31 December 2024: approximately 0.3%).

The unrealised foreign exchange losses in equity instruments at FVTOCI was approximately RMB0.7 million for the six months ended 30 June 2025 (corresponding period of 2024: gains approximately RMB0.2 million), and the gains from changes in fair value of equity instruments at FVTOCI was approximately RMB27.0 million (corresponding period of 2024: losses approximately RMB93.2 million).



## MANAGEMENT DISCUSSION AND ANALYSIS

Jenscare Scientific is a medical device company dedicated to the development of interventional products for the treatment of structural heart diseases. Established in 2011, it has developed a series of treatment solutions targeting different types of structural heart diseases, including tricuspid valve diseases, aortic valve diseases, mitral valve diseases and heart failure. The shares of Jenscare Scientific are listed on The Stock Exchange of Hong Kong Limited (the "Stock Exchange") (stock code: 9877). The Group held 5,646,600 H shares in Jenscare Scientific, representing approximately 1.8% of its total issued share capital as at 30 June 2025.

The investment is classified as equity instruments at FVTOCI in accordance with IFRS 9. Additional information in relation to the investment is set out in Note 14 to the condensed consolidated financial statements in this interim report. In the opinion of the Directors, the above investment is held for long-term strategic investment purposes and, as such, the above investment is classified as non-current asset.

## LIQUIDITY AND FINANCIAL RESOURCES

During the six months ended 30 June 2025, the Group mainly financed its operations with its own working capital.

The Group recorded total current assets of approximately RMB2,573.3 million as at 30 June 2025 (31 December 2024: approximately RMB2,334.2 million) and total current liabilities of approximately RMB993.3 million as at 30 June 2025 (31 December 2024: approximately RMB815.6 million). As at 30 June 2025, the total current liabilities of the Group primarily included trade and other payables amounting to approximately RMB841.3 million (31 December 2024: approximately RMB758.2 million). Other payables primarily included accrued expenses of approximately RMB169.2 million (31 December 2024: approximately RMB166.0 million) primarily in relation to clinical expenses and exhibition expenses, as well as accrued payroll and bonus of approximately RMB114.7 million (31 December 2024: approximately RMB107.4 million).

Trade receivables in terms of debtor turnover days was 45 days (31 December 2024: 33 days), and trade payables in terms of creditor turnover days was 72 days (31 December 2024: 103 days).

The current ratio (calculated by dividing the total current assets by the total current liabilities) of the Group was approximately 2.59 as at 30 June 2025 (31 December 2024: approximately 2.86).

## BORROWINGS

As at 30 June 2025 and 31 December 2024, the Group did not have any bank borrowings.

## CASH AND CASH EQUIVALENTS

As at 30 June 2025, the Group's cash and cash equivalents were approximately RMB782.6 million, representing an increase of approximately 17.5% from approximately RMB665.8 million as at 31 December 2024. The cash and cash equivalents of the Group were mainly denominated in Renminbi and Hong Kong Dollars.

## GEARING RATIO

As at 30 June 2025 and 31 December 2024, the Group did not have any bank borrowings, and the gearing ratio of the Group (calculated based on the ratio of total bank borrowings to total equity) was zero.

## CAPITAL STRUCTURE

Total equity attributable to equity holders of the Company amounted to approximately RMB3,770.2 million as at 30 June 2025 as compared with approximately RMB3,494.5 million as at 31 December 2024.

## TREASURY POLICY

The Directors will continue to follow a prudent policy in managing the Group's financial resources such as cash, with the objective of maintaining a strong and healthy liquidity position to ensure that the Group is well-placed to seize future growth opportunities whenever such opportunities arises.

## PROPERTY HELD

On 26 June 2019, Dongguan LifeTech Medical Co., Ltd. (東莞市先健醫療有限公司) ("Dongguan LifeTech"), a wholly-owned subsidiary of the Company entered into a land use right transfer contract with the Dongguan Natural Resources Bureau (東莞市自然資源局) for the acquisition of land use right of a land which has a site area of 43,604 square meters located at the southeast of the intersection of South 1 Road and South 8 Road in eastern Songshan Lake, Dongguan, Guangdong, the People's Republic of China ("PRC") (the "Land"). The land use right is wholly-owned by the Group which was acquired at a total consideration of approximately RMB43.6 million.

On 24 April 2020, Dongguan LifeTech entered into a construction contract with China Construction Second Engineering Bureau Limited for the construction of an industrial park above the Land. The industrial park covers a total site area of approximately 43,604 square meters and can cater for the Group's day-to-day business and operational needs in Dongguan and nearby regions. The contract price for the construction works is up to a maximum aggregate amount of RMB620.0 million. The construction contract was approved by independent shareholders by way of poll at the extraordinary general meeting ("EGM") of the Company held on 30 June 2020. For further details and information, please refer to the Company's announcements dated 26 June 2019, 24 April 2020 and 30 June 2020 and the circular dated 9 June 2020.

In May 2023, the Company had obtained property ownership certificates of all buildings and basements. As at 30 June 2025, a portion of the total gross floor area of the industrial park has been allocated for the Company's own operations and external tenant leasing, with the remaining area reserved for future allocation.

## MATERIAL ACQUISITIONS AND DISPOSALS OF SUBSIDIARIES, ASSOCIATES AND JOINT VENTURES

On 6 June 2025, the Company, through its wholly-owned subsidiary, Lifetech Shenzhen, entered into a series of agreements in relation to the proposed investment in Affector Medtech (Suzhou) Ltd. (劍虎醫療科技(蘇州)有限公司) ("Affector Medtech"), a high-tech company established in the PRC specializing in the field of electrophysiology and innovative medical devices (the "Investment").

## MANAGEMENT DISCUSSION AND ANALYSIS

Lifetech Shenzhen has agreed to invest a total of RMB150.0 million in Affector Medtech in cash. The Investment will be made in stages, subject to the achievement of certain milestones as set out in the investment agreement, including the founders and core team of Affector Medtech entering into employment contracts, confidentiality agreements, and non-competition agreements satisfactory to Lifetech Shenzhen, as well as Affector Medtech obtaining NMPA registration certificates for certain specific products.

Part of the Investment will be used to increase the registered capital of Affector Medtech, while the remaining amount will be credited to capital reserve. After completion of all stages of the Investment, Lifetech Shenzhen will be entitled to 30% of the equity interest in Affector Medtech. As at the date of this interim report, the first stage of the investment has been completed, and Lifetech Shenzhen has acquired a 22.22% equity interest in Affector Medtech.

Save as disclosed above, there were no other material acquisitions and disposals of subsidiaries, associates and joint ventures during the six months ended 30 June 2025.

### SIGNIFICANT INVESTMENTS AND FUTURE PLANS FOR MATERIAL INVESTMENTS OR CAPITAL ASSETS

Save as disclosed in this interim report, there were no significant investments held by the Company with a value greater than 5% of its total assets as at 30 June 2025, nor was there any plan authorised by the Board for other material investments or additions of capital assets as at the date of this interim report.

The Group's investment strategy for significant investments is to identify investment opportunities with growth potential within the healthcare industry and seek opportunities for strategic cooperation. We hold our investments in equity instruments. Our investment objective is to form long-term strategic partnerships with companies in the medical industry with the potential of enriching our product lines and expanding our business scale, thereby maximising shareholders' interests and value.

### CONTINGENT LIABILITIES

The Group did not have any significant contingent liabilities as at 30 June 2025.

### FINANCIAL INSTRUMENT

As at 30 June 2025, the Group did not have any outstanding hedge contracts or financial derivative instruments.

### CAPITAL EXPENDITURE

During the six months ended 30 June 2025, the capital expenditure of the Group for property, plant and equipment, construction in progress, intangible assets, right-of-use assets and deposits for property, plant and equipment amounted to approximately RMB56.7 million (corresponding period of 2024: approximately RMB213.2 million).

## FOREIGN EXCHANGE EXPOSURE

During the six months ended 30 June 2025, the Group primarily conducted its operations in both Asia and Europe. The revenue generated from Asia (excluding China's mainland) and Europe accounted for approximately 11.4% and 11.0%, respectively, of the Group's total revenue for the six months ended 30 June 2025 (corresponding period of 2024: approximately 10.9% and 10.0%, respectively). The operational results and financial condition of the Group may be affected by fluctuations in exchange rates involving the currencies used in its business transactions.

Although the Group did not implement any hedging strategies to mitigate this exposure during the Reporting Period, the management closely monitored foreign currency exposure to maintain net exposure at an acceptable level. The Group expects that exchange rate fluctuations will not have a material adverse effect on its operations in the foreseeable future. However, the Group will consider hedging significant foreign currency exposure should the need arise.

## CHARGES ON GROUP ASSETS

As at 30 June 2025, the Group did not have any charges on its assets.

## CAPITAL COMMITMENT

As at 30 June 2025, the Group's capital expenditure contracted for but not provided in the condensed consolidated financial statements amounted to approximately RMB46.3 million (31 December 2024: approximately RMB55.1 million).

## SEGMENT INFORMATION

During the six months ended 30 June 2025, the revenue of the Group was principally generated from the structural heart diseases business, the peripheral vascular diseases business and the cardiac pacing and electrophysiology business. An aging population, urbanisation and the continuous improvement of health awareness by the public, are all factors which contribute to the steady growth of the healthcare industry. These trends, along with our R&D efforts, suggest that there will be an increased demand for our products in the future, thus leading to business growth.

### STRUCTURAL HEART DISEASES BUSINESS

The Company has developed four generations of congenital heart diseases occluders to satisfy various patients' needs, and to achieve differentiated marketing strategies. At the same time, we continue to upgrade the LAA occluder to meet the growing treatment demand with innovative technology. Driven by a large number of patients with atrial fibrillation around the world, the global market for the LAA occluder is expected to keep growing in the future.

### PERIPHERAL VASCULAR DISEASES BUSINESS

The Company provides patients with technology-leading systemic and comprehensive interventional medical devices treatment solutions of peripheral vascular diseases. Among those products, the market shares of vena cava filters and stent grafts occupy a leading position in the domestic market. An aging population, increase in diseases detection rate and expansion of product applications are factors that would help drive the growth of market demand for these products.



## MANAGEMENT DISCUSSION AND ANALYSIS

### CARDIAC PACING AND ELECTROPHYSIOLOGY BUSINESS

The Company is the first manufacturer in China that has a complete product portfolio of domestic implantable cardiac pacemakers with international-level technology and functions.

Please refer to the paragraph headed “Financial Review – Revenue” above for the financial performance of these business segments. Financial information related to these aspects is presented in Note 4 to the condensed consolidated financial statements in this interim report.

### EMPLOYEES AND REMUNERATION POLICY

As at 30 June 2025, the Group had 1,273 full-time employees (31 December 2024: 1,392) and three executive Directors (31 December 2024: three). Total staff costs, including Directors' emoluments, amounted to approximately RMB359.6 million for the six months ended 30 June 2025 (corresponding period of 2024: approximately RMB228.2 million).

The employees of the Group who operate in the PRC are members of a state-managed retirement benefits scheme operated by the PRC government under which the employees are entitled to a monthly pension after retirement. The Group is required to contribute a certain percentage of employee's salaries to the retirement benefits scheme to fund the benefits. The only obligation of the Group with respect to the retirement benefits scheme is to make the aforementioned specified contributions. The Group operates the Mandatory Provident Fund Scheme for all qualifying employees in Hong Kong. Contributions to these schemes are expensed as incurred. During the six months ended 30 June 2025, the total cost paid or payable in relation to contributions to the retirement benefits scheme was approximately RMB18.7 million (corresponding period of 2024: approximately RMB18.0 million). Forfeited contributions (by the Group on behalf of the employees who leave the aforesaid schemes prior to vesting fully in such contributions) may not be used by the Group to reduce the existing level of contributions.

The Group's remuneration policies were determined with reference to the performance, qualification and working experience of individual employees, as well as the results of the Group and the market conditions. The benefits provided by the Group to its employees include discretionary bonus, transportation and meal subsidies, basic and group medical insurance, work injury insurance, unemployment insurance, annual physical examination, share options, etc. We have a fair and effective performance appraisal system and schemes designed to motivate and reward employees at all levels for their performance and achievements. The Company adopted a share option scheme on 22 October 2011, which was subsequently amended by unanimous written resolutions of the Board on 5 May 2015. On 17 September 2021, as the number of share options which may be granted under such share option scheme had reached its limit and would soon expire, the Company terminated such share option scheme and adopted a new share option scheme to provide incentives for employees of the Group and other eligible participants thereunder. The Company has adopted a share award scheme on 28 December 2018, which was subsequently amended by unanimous written resolutions of the Board on 29 April 2019. The Company also adopted another share award scheme on 3 March 2022.

Employees are the cornerstone of enterprise development, and the Group is committed to providing all employees with a safe and comfortable working environment, opportunities of equal employment, trainings and career development, such as orientation programmes for new employees, regulation-related trainings and position skills trainings. The Group has also established a labour union to safeguard the legitimate rights of its employees and to further promote the Group's sustainable, stable and healthy development.

## THE 2020 PLACING

On 11 December 2020, the Company completed a placing of an aggregate of 287,320,000 new ordinary shares of the Company, with an aggregate nominal value of USD359.15, at a placing price of HKD3.2368 per share pursuant to a placing agreement dated 4 December 2020 (the "2020 Placing").

Pursuant to the 2020 Placing, an aggregate of 287,320,000 new ordinary shares, representing approximately 6.21% of the issued share capital of the Company as enlarged by the allotment and issue of the new shares immediately after the completion of the 2020 Placing, have been successfully placed to not less than six placees who and whose ultimate beneficial owner(s), to the best of the knowledge, information and belief of the Directors having made all reasonable enquiries, are independent of the Company. None of the placees and their respective ultimate beneficial owners have become a substantial shareholder (as defined under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules")) of the Company as a result of the placing.

The placing price of HKD3.2368 per placing share represents:

- (i) a discount of approximately 11.6% to the closing price of HKD3.660 per share of the Company as quoted on the Stock Exchange on 3 December 2020, being the trading day prior to the date of the placing agreement;
- (ii) a discount of approximately 9.3% to the average closing price of approximately HKD3.570 per share of the Company as quoted on the Stock Exchange for the five consecutive trading days immediately prior to the date of the placing agreement; and
- (iii) a discount of approximately 2.3% to the average closing price of approximately HKD3.313 per share of the Company as quoted on the Stock Exchange for the ten consecutive trading days immediately prior to the date of the placing agreement.

The net placing price (after deducting the costs and expenses incurred for the 2020 Placing) was approximately HKD3.2366 per placing share. The net proceeds raised from the 2020 Placing were approximately HKD930.0 million.

As at 30 June 2025, approximately HKD391.2 million brought forward from the net proceeds received by the Company from the 2020 Placing remained unutilised.

## MANAGEMENT DISCUSSION AND ANALYSIS

As at 30 June 2025, the details and usage of the proceeds from the 2020 Placing were as follows:

Intended use of proceeds	Approximate allocation of net proceeds as previously disclosed (HKD in million)	Approximate amount of net proceeds unutilised as at 31 December 2024 (HKD in million)	Approximate utilisation of proceeds during the six months ended 30 June 2025 (HKD in million)	Approximate amount of net proceeds unutilised as at 30 June 2025 (HKD in million)	Expected timeline for utilisation of unutilised proceeds
Repayment of certain bank borrowings of the Group	406.0	—	—	—	Fully utilised
Funding potential business development involving a new overseas clinical project	465.0	398.9	7.7	391.2	To be applied in the second half of 2025 (HKD20.0 million), 2026 (HKD155.0 million) and 2027 (HKD216.2 million) subject to adjustments (if any)
General working capital of the Group	59.0	—	—	—	Fully utilised
<b>Total</b>	<b>930.0</b>	<b>398.9</b>	<b>7.7</b>	<b>391.2</b>	

Approximately HKD7.7 million of the net proceeds of the 2020 Placing had been utilised during the six months ended 30 June 2025 in accordance with the intended use of proceeds. There has been no change in the intended use of net proceeds. The unutilised net proceeds from the 2020 Placing would be brought forward to the next financial period/year and will be gradually utilised in accordance with the above intended purposes.

The Directors consider that the 2020 Placing represented an opportunity to raise capital while broadening its capital and shareholder base. The Directors were of the view that the 2020 Placing would strengthen the financial position of the Company and provide working capital to the Company.

For further details, please refer to the Company's announcements dated 4 December 2020 and 11 December 2020.

### EVENTS AFTER THE REPORTING PERIOD

There have not been any significant events affecting the Group after 30 June 2025.

## FUTURE PROSPECTS

The global medical device industry continues to present significant growth opportunities, driven by demographic shifts, technological advancements, and increasing healthcare demands. Although the expansion of the coverage of China's centralized procurement policies has exerted pricing pressure on medical device products, it has also accelerated industry consolidation, prompting companies to place greater emphasis on innovation and differentiated competition. Leveraging strong R&D capabilities, a diversified product portfolio, and a growing global presence, the Company has established a resilient competitive advantage, enabling us to proactively capture industry opportunities and drive sustained and stable business growth.

Our strategic investment in Affector Medtech represents a key milestone in strengthening our position in the high-growth electrophysiology market. This partnership provides access to cutting-edge technologies and enhances our ability to offer comprehensive solutions to customers globally. We expect this collaboration to create meaningful synergies and contribute to our long-term growth, particularly as we leverage our overseas distribution network to commercialize these innovative products.

Looking ahead, we will continue to focus on expanding our international footprint while maintaining operational efficiency across our business. Our commitment to innovation remains unwavering, with ongoing investments in new technologies and product development to address evolving market needs. At the same time, we will maintain disciplined capital allocation to ensure sustainable growth and value creation for all stakeholders.

The Company is confident in its ability to navigate both challenges and opportunities in the evolving healthcare landscape. By staying true to our core strengths in innovation and execution, we are well-positioned to deliver long-term growth and reinforce our leadership in the global medical device industry. We remain committed to creating value for patients, healthcare providers, and shareholders through our continued focus on technological advancement and operational excellence.



# CORPORATE GOVERNANCE HIGHLIGHTS

## COMPLIANCE WITH THE CORPORATE GOVERNANCE CODE

The Company is committed to achieving high standards of corporate governance to safeguard the interests of its shareholders (the "Shareholders") and enhance its corporate value. The Company has applied the principles as set out in the Corporate Governance Code (the "CG Code") contained in Appendix C1 to the Listing Rules as its own code of corporate governance and confirms that it has complied with all code provisions of the CG Code during the six months ended 30 June 2025, save for the deviation from code provision C.2.1 of the CG Code as mentioned below.

According to code provision C.2.1 of the CG Code, the roles of the Chairman and Chief Executive Officer should be separate and should not be performed by the same individual. Subsequent to the resignation of former Chief Executive Officer of the Company, Mr. XIE Yuehui, Chairman of the Board, has been appointed to act as the Chief Executive Officer of the Company on 2 March 2015. Accordingly, the roles of the Chairman of the Board and the Chief Executive Officer are performed by the same individual. Although the dual roles of the Chairman and Chief Executive Officer is a deviation from the code provision C.2.1 of the CG Code, the Board believes that vesting the roles of both Chairman and Chief Executive Officer in an experienced and qualified person such as Mr. XIE Yuehui provides the Company with strong and consistent leadership while allowing for effective and efficient planning and implementation of business decisions and strategies.

The Board reviews the corporate governance structure and practices from time to time and shall make necessary arrangements when the Board considers appropriate.

## THE BOARD

The Board currently comprises seven Directors, including three executive Directors, namely Mr. XIE Yuehui, Mr. LIU Jianxiong and Ms. RUAN Xingmei; one non-executive Director, namely Mr. JIANG Feng; and three independent non-executive Directors with at least one independent non-executive Director possessing appropriate professional qualifications, or accounting or related financial management expertise, namely Mr. LIANG Hsien Tse Joseph, Mr. WANG Wansong and Mr. ZHOU Luming.

Further to the Company's announcement on 23 May 2025, Ms. RUAN Xingmei, an executive Director, and Mr. WANG Wansong, an independent non-executive Director, have been appointed as members of the nomination committee of the Company.

**MODEL CODE FOR SECURITIES TRANSACTIONS**

The Company has adopted the Model Code for Securities Transactions by Directors of Listed Issuers (the “Model Code”) as set out in Appendix C3 to the Listing Rules as its own code of conduct for dealing in securities of the Company by the Directors on terms no less exacting than the required standard set out in the Model Code.

Having made specific enquiries with all the Directors, the Company confirmed that all members of the Board complied with the Model Code during the six months ended 30 June 2025.

Senior management, executives and staff members who, because of their offices in the Company, are likely to possess inside information, have also been requested to comply with the provision of the Model Code. No incident of non-compliance with the Model Code by such employees was noted by the Company during the six months ended 30 June 2025.

**AUDIT COMMITTEE AND REVIEW OF INTERIM REPORT**

The Board has established an audit committee (the “Audit Committee”) in accordance with the corporate governance requirements of listed companies of the Stock Exchange. As at the date of this interim report, the Audit Committee consists of three members, all of whom are independent non-executive Directors, namely Mr. LIANG Hsien Tse Joseph who possesses appropriate professional qualifications to serve as its Chairman, Mr. ZHOU Luming and Mr. WANG Wansong.

The Group’s unaudited interim report for the six months ended 30 June 2025 and accounting principles have been reviewed and discussed by the Audit Committee, which was of the opinion that the preparation of such results was in compliance with the relevant accounting standards, the Listing Rules and the applicable legal requirements, and that adequate disclosure has been made.

## OTHER INFORMATION

### DIRECTORS' AND CHIEF EXECUTIVES' INTERESTS AND SHORT POSITIONS IN SHARES, UNDERLYING SHARES AND DEBENTURES OF THE COMPANY AND ITS ASSOCIATED CORPORATIONS

As at 30 June 2025, the interests and short positions of the Directors and chief executives of the Company in the shares, underlying shares and debentures of the Company or any of its associated corporations (within the meaning of Part XV of the Securities and Futures Ordinance (the "SFO")) which were required (a) to be notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests and short positions which they are taken or deemed to have under such provisions of the SFO), or (b) to be and were entered into the register required to be kept by the Company pursuant to Section 352 of the SFO, or (c) as otherwise notified to the Company and the Stock Exchange pursuant to the Model Code were as follows:

#### LONG POSITIONS IN SHARES AND UNDERLYING SHARES OF THE COMPANY

Name of Directors	Capacity	Number of share(s) of the Company ("Share(s)") (long position)	Approximate percentage of shareholding
Mr. XIE Yuehui	Interest of controlled corporation and beneficial owner	698,794,928 (Note 1)	15.09%
Mr. LIU Jianxiong	Beneficial owner	44,140,000 (Note 2)	0.95%
Ms. RUAN Xingmei	Beneficial owner	4,600,000 (Note 3)	0.10%

Notes:

- These interests represented:
  - 694,194,928 shares held by Xianjian Advanced Technology Limited, which are wholly owned by Mr. XIE Yuehui, the Chairman, Chief Executive Officer and executive Director; and
  - 4,600,000 options granted to Mr. XIE Yuehui on 24 January 2024, which were subject to certain vesting conditions pursuant to the Share Option Scheme of the Company, details of which are set out in the section headed "Share Option Scheme" in this interim report.
- These interests represented:
  - 8,140,000 shares held by Mr. LIU Jianxiong, the Executive Vice President, executive Director, Chief Financial Officer and company secretary; and
  - 36,000,000 options granted to Mr. LIU Jianxiong on 24 January 2024, which were subject to certain vesting conditions pursuant to the Share Option Scheme of the Company, details of which are set out in the section headed "Share Option Scheme" in this interim report.

3. These interests represented:

- (a) 180,000 shares held by Ms. RUAN Xingmei, the Chief Compliance Officer and an executive Director, which were granted and vested pursuant to the 2022 Share Award Scheme;
- (b) 1,000,000 options granted to Ms. RUAN Xingmei on 31 March 2021, 1,500,000 options granted to Ms. RUAN Xingmei on 12 November 2021, and 1,500,000 options granted to Ms. RUAN Xingmei on 24 January 2024 respectively, which were subject to certain vesting conditions pursuant to the Previous Scheme and Share Option Scheme of the Company, details of which are set out in the section headed "Share Option Scheme" in this interim report; and
- (c) 420,000 2022 Scheme Award Shares granted to Ms. RUAN Xingmei on 21 October 2022, which were subject to certain vesting conditions pursuant to the 2022 Share Award Scheme of the Company, details of which are set out in the section headed "Share Award Scheme" in this interim report.

Save as disclosed above, as at 30 June 2025, so far as is known to any Directors or chief executives of the Company, none of the Directors or chief executives of the Company had any interests or short positions in the shares, underlying shares and debentures of the Company or its associated corporations (within the meaning of Part XV of the SFO) which were required (a) to be notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests and short positions which they were taken or deemed to have under such provisions of the SFO), or (b) to be entered in the register required to be kept by the Company pursuant to section 352 of the SFO, or (c) as otherwise to be notified to the Company and the Stock Exchange pursuant to the Model Code.

## **SUBSTANTIAL SHAREHOLDERS' INTERESTS AND SHORT POSITIONS IN SHARES AND UNDERLYING SHARES OF THE COMPANY**

As at 30 June 2025, other than the interests of Directors or chief executives of the Company as disclosed under the section headed "DIRECTORS' AND CHIEF EXECUTIVES' INTERESTS AND SHORT POSITIONS IN SHARES, UNDERLYING SHARES AND DEBENTURES OF THE COMPANY OR ITS ASSOCIATED CORPORATIONS" above, the interests and short positions of persons in the shares and underlying shares of the Company which would fall to be disclosed under the provisions of Divisions 2 and 3 of Part XV of the SFO as recorded in the register required to be kept by the Company under section 336 of the SFO, or who was, directly or indirectly, interested in 5% or more of the issued shares, were as follows:



## OTHER INFORMATION

### LONG POSITIONS IN SHARES OF THE COMPANY

Name of Shareholders	Capacity	Number of Shares (long position)	Approximate percentage of shareholding
Xianjian Advanced Technology Limited (Note 1)	Beneficial owner	694,194,928	14.99%
Futu Trustee Limited (Note 2)	Trustee	208,507,500	4.50%
	Custodian (other than an exempt custodian interest)	26,250,500	0.57%

Notes:

1. The entire issued share capital of Xianjian Advanced Technology Limited is wholly owned by Mr. XIE Yuehui, the Chairman, Chief Executive Officer and an executive Director of the Company.
2. Futu Trustee Limited holds 26,250,500 shares as the custodian of the vested shares of one Director and the employees of the 2022 Share Award Scheme trust.

Save as disclosed above, as at 30 June 2025, the Directors have not been notified by any person (other than the Directors or chief executives of the Company) who had interests or short positions in the shares or underlying shares as recorded in the register required to be kept pursuant to Section 336 of the SFO.

### SHARE OPTION SCHEME

The previous share option scheme (the "Previous Scheme") adopted by the Company on 22 October 2011, which was amended by a unanimous written resolution of the Board on 5 May 2015, was terminated pursuant to an ordinary resolution passed by the shareholders at the EGM on 17 September 2021. A new share option scheme (the "Share Option Scheme") in place of the Previous Scheme was adopted by the Company with effect from 17 September 2021 which has a term of 10 years.

#### 1. PURPOSE OF THE SHARE OPTION SCHEME

The purpose of the Share Option Scheme is to enable the Company to grant options to the Share Option Scheme Eligible Participants (as defined below) as incentives or rewards for their contribution to the growth of the Group and to provide the Group with a more flexible means to reward, remunerate, compensate and/or provide benefits to the Share Option Scheme Eligible Participants.

## **2. PARTICIPANTS OF THE SHARE OPTION SCHEME AND THE BASIS OF DETERMINING THE ELIGIBILITY OF THE PARTICIPANTS**

The Board may at its discretion grant options to any full-time or part-time employees, Directors (including executive, non-executive or independent non-executive), any consultants or advisers (whether professional or otherwise), supplier, service provider, customer, business partner, shareholder, any person or entity that provides design, R&D or other technological support and any other group or classes of participants who have contributed or may contribute to the development and growth of our Company and/or any entity in which our Company holds an equity interest (collectively the "Share Option Scheme Eligible Participants").

## **3. MAXIMUM NUMBER OF SHARES**

The total number of shares which may be issued upon exercise of all options to be granted under the Share Option Scheme and any other share option schemes of our Group is 462,929,240, being not more than 10% of the issued share capital of the Company as at 17 September 2021, adoption date of the Share Option Scheme. Any options lapsed in accordance with the terms of the Share Option Scheme or any other share option scheme of the Group shall not be counted for the purpose of calculating the Scheme Mandate Limit.

As at the date of this interim report, the maximum number of further share options that may be granted under the Share Option Scheme was 151,379,240, representing approximately 3.27% of the number of total issued shares of the Company. No further share options may be granted under the Previous Scheme. There is no service provider sublimit under the Share Option Scheme.

## **4. MAXIMUM ENTITLEMENT OF EACH PARTICIPANT**

Unless approved by the shareholders in the manner set out in the Share Option Scheme, the total number of shares issued and to be issued upon exercise of the options granted to each Share Option Scheme Eligible Participant (including both exercised and outstanding options under the Share Option Scheme) in any 12-month period must not exceed 1% of the issued share capital of the Company.

## **5. OFFER PERIOD AND AMOUNT PAYABLE FOR OPTIONS**

An offer of grant of an option shall remain open for acceptance by the Share Option Scheme Eligible Participants concerned for such period as determined by the Board, which period shall not be more than fourteen (14) days from the date of the offer, provided that no such offer shall be open for acceptance after the tenth anniversary of 17 September 2021 or after the Share Option Scheme has been terminated in accordance with the provisions thereof. Upon acceptance of the offer, the grantee may be asked to pay HKD1.00 to the Company by way of consideration for the grant and the date on which the option is offered shall be deemed to be the date of grant of the relevant option, except in determining the date of grant for the purpose of calculating the subscription price.

## OTHER INFORMATION

### 6. MINIMUM PERIOD FOR WHICH AN OPTION MUST BE HELD BEFORE IT CAN BE EXERCISED

There is no general requirement on the minimum period for which an option must be held or the performance targets which must be achieved before an option can be exercised under the terms of the Share Option Scheme. However, the Board may offer to grant any options subject to such terms and conditions in relation to the minimum period of the options to be held and/or the performance targets to be achieved before such options can be exercised as the Board may determine in its absolute discretion.

### 7. BASIS OF DETERMINING THE SUBSCRIPTION PRICE

The subscription price for shares in respect of any particular option granted under the Share Option Scheme shall be such price as the Board shall determine, provided that such price shall be at least the highest of:

- (i) the closing price per share as stated in the Stock Exchange's daily quotation sheet on the date of offer of the option;
- (ii) the average closing price per share as stated in the Stock Exchange's daily quotation sheets for the five (5) business days immediately preceding the date of offer of the option; and
- (iii) the nominal value of a share.

### 8. REMAINING LIFE OF THE SHARE OPTION SCHEME

Subject to the fulfilment of the conditions of the Share Option Scheme and the earlier termination by shareholders' resolution in general meeting or the Board, the Share Option Scheme shall be valid and effective for a period of ten (10) years commencing from 17 September 2021, after which period no further options will be offered or granted but the provisions of the Share Option Scheme shall remain in full force and effect in all other respects with respect to options granted during the life of the Share Option Scheme. The remaining life of the Share Option Scheme is approximately six years and three months as at 30 June 2025.

The table below sets out details of the outstanding share options granted to the Directors and other grantees under the Previous Scheme and movements during the period from 1 January 2025 to 30 June 2025:

					Number of shares					
					Granted on the date of grant	Outstanding as at 1 January 2025	Exercised during the six months ended 30 June 2025	Closing price (weighted average) of the shares of the Company immediately before the dates on which the options were exercised	Lapsed/ cancelled during the six months ended 30 June 2025	Outstanding as at 30 June 2025
Name	Date of grant	Vesting schedule	Option period	Exercise price						
Directors/Chief Executives										
Mr. XIE Yuehui	5 May 2015	20% of options on 5 May 2016, 2017, 2018, 2019 and 2020 respectively	10 years from the date of grant	HKD1.464	19,600,000	19,600,000	—	—	(19,600,000)	—
Sub-total					19,600,000	19,600,000	—	—	(19,600,000)	—
Mr. LIU Jianxiong	5 May 2015	20% of options on 5 May 2016, 2017, 2018, 2019 and 2020 respectively	10 years from the date of grant	HKD1.464	16,800,000	16,800,000	—	—	(16,800,000)	—
Sub-total					16,800,000	16,800,000	—	—	(16,800,000)	—
Ms. RUAN Xingmei	31 March 2021	30%, 30%, 40% of options on 31 March 2022, 2023 and 2024 respectively	10 years from the date of grant	HKD3.570	1,000,000	1,000,000	—	—	—	1,000,000
Sub-total					1,000,000	1,000,000	—	—	—	1,000,000
Other Grantees										
Employees	5 May 2015	20% of options on 5 May 2016, 2017, 2018, 2019 and 2020 respectively	10 years from the date of grant	HKD1.464	123,600,000	32,659,600 (Note 1)	(1,100,000)	HKD 1.419	(31,559,600) (Note 2)	—
Employees	31 March 2021	30%, 30%, 40% of options on 31 March 2022, 2023 and 2024 respectively	10 years from the date of grant	HKD3.570	32,320,000	25,250,000 (Note 3)	—	—	(400,000)	24,850,000 (Note 4)
Sub-total					155,920,000	57,909,600	(1,100,000)	HKD1.419	(31,959,600)	24,850,000
Total					193,320,000	95,309,600	(1,100,000)	HKD 1.419	(68,359,600)	25,850,000

Note 1: The 32,659,600 outstanding share options as at 1 January 2025 were held by 18 grantees who were employees of the Group.

Note 2: The 31,559,600 outstanding share options were automatically lapsed on 5 May 2025 due to expiration of the option period.

Note 3: The 25,250,000 outstanding share options as at 1 January 2025 were held by 96 grantees who were employees of the Group.

Note 4: The 24,850,000 outstanding share options as at 30 June 2025 were held by 93 grantees who were employees of the Group.



## OTHER INFORMATION

As at 30 June 2025, 25,850,000 share options were granted and remained outstanding pursuant to the Previous Scheme.

The table below sets out details of the outstanding share options granted to the Directors and other grantees under the Share Option Scheme and movements during the period of 1 January 2025 to 30 June 2025:

					Number of shares					
					Granted on the date of grant	Outstanding as at 1 January 2025	Exercised during the six months ended 30 June 2025	Closing price (weighted average) of the shares of the Company immediately before the dates on which the options were exercised	Lapsed/ cancelled during the six months ended 30 June 2025	Outstanding as at 30 June 2025
Name	Date of grant	Vesting schedule	Option period	Exercise price						
Directors/Chief Executives										
Mr. XIE Yuehui	24 January 2024 (Note 1)	15%, 15%, 20%, 25% and 25% upon completion of the Group's annual performance assessment of 2024, 2025, 2026, 2027 and 2028, respectively	10 years from the date of grant	HKD1.950	4,600,000	4,600,000	—	—	—	4,600,000
Sub-total					4,600,000	4,600,000	—	—	—	4,600,000
Mr. LIU Jianxiong	24 January 2024 (Note 1)	15%, 15%, 20%, 25% and 25% upon completion of the Group's annual performance assessment of 2024, 2025, 2026, 2027 and 2028, respectively	10 years from the date of grant	HKD1.950	36,000,000	36,000,000	—	—	—	36,000,000
Sub-total					36,000,000	36,000,000	—	—	—	36,000,000
Ms. RUAN Xingmei	12 November 2021	10%, 15%, 20%, 25% and 30% upon completion of the Group's annual performance assessment of 2022, 2023, 2024, 2025 and 2026, respectively	10 years from the date of grant	HKD3.590	1,500,000	1,500,000	—	—	—	1,500,000
Ms. RUAN Xingmei	24 January 2024 (Note 1)	15%, 15%, 20%, 25% and 25% upon completion of the Group's annual performance assessment of 2024, 2025, 2026, 2027 and 2028, respectively	10 years from the date of grant	HKD1.950	1,500,000	1,500,000	—	—	—	1,500,000
Sub-total					3,000,000	3,000,000	—	—	—	3,000,000

					Number of shares					
					Granted on the date of grant	Outstanding as at 1 January 2025	Exercised during the six months ended 30 June 2025	Closing price (weighted average) of the shares of the Company immediately before the dates on which the options were exercised	Lapsed/ cancelled during the six months ended 30 June 2025	Outstanding as at 30 June 2025
Name	Date of grant	Vesting schedule	Option period	Exercise price						
Other Grantees										
Employees	12 November 2021	10%, 15%, 20%, 25% and 30% upon completion of the Group's annual performance assessment of 2022, 2023, 2024, 2025 and 2026, respectively	10 years from the date of grant	HKD3.590	100,300,000	85,935,000	—	—	(3,545,000)	82,390,000 (Note 2)
Employees	10 December 2021	10%, 15%, 20%, 25% and 30% upon completion of the Group's annual performance assessment of 2022, 2023, 2024, 2025 and 2026, respectively	10 years from the date of grant	HKD3.836	11,000,000	10,410,000	—	—	(140,000)	10,270,000 (Note 3)
Consultants	10 December 2021	10%, 15%, 20%, 25% and 30% upon completion of the Group's annual performance assessment of 2022, 2023, 2024, 2025 and 2026, respectively	10 years from the date of grant	HKD3.836	24,000,000	24,000,000	—	—	—	24,000,000 (Note 4)
Employees	24 January 2024 (Note 1)	15%, 15%, 20%, 25% and 25% upon completion of the Group's annual performance assessment of 2024, 2025, 2026, 2027 and 2028, respectively	10 years from the date of grant	HKD1.950	132,650,000	129,950,000	—	—	(4,032,500)	125,917,500
Sub-total					267,950,000	250,295,000	—	—	(7,717,500)	242,577,500
Total					311,550,000	293,895,000	—	—	(7,717,500)	286,177,500

Note 1: The exercise of the share options granted on 24 January 2024 is also subject to the grantees meeting their respective performance targets as determined by the Company. The fair value of share options at the date of grant is HKD0.9895 per share. The closing price of the shares of the Company immediately before the date on which the share options were granted (i.e. 24 January 2024) was HKD1.890 per share. The 168,017,500 outstanding share options as at 30 June 2025 were held by 207 grantees who are employees or Directors of the Group.

Note 2: The 82,390,000 outstanding share options as at 30 June 2025 were held by 134 grantees who are employees of the Group.

Note 3: The 10,270,000 outstanding share options as at 30 June 2025 were held by 19 grantees who are employees of the Group.

Note 4: The 24,000,000 outstanding share options as at 30 June 2025 were held by 5 grantees who are consultants of the Group.

## OTHER INFORMATION

As at 30 June 2025, 286,177,500 share options were granted and remained outstanding pursuant to the Share Option Scheme. The number of options available for further grant under the Share Option Scheme as at 1 January 2025 and 30 June 2025 were both 151,379,240.

As at 30 June 2025, there was no participant with share options granted in excess of the 1% individual limit as defined under Chapter 17 of the Listing Rules.

### VALUE OF SHARE OPTIONS

The Binomial Model had been used to estimate the fair value of the share options. The model involves the construction of a binomial lattice which represents different possible paths that might be followed by the stock price over the life of the options. In developing the binomial lattice, the life of the options is divided into various time steps. In each time step there is a binomial stock price movement. The main inputs to the model include the share price of the Company, exercise price, exercise multiple, risk-free rate, expected volatility, dividend yield and expected life of the options.

#### *VALUE OF SHARE OPTIONS GRANTED ON 31 MARCH 2021*

The fair value of the share options granted on 31 March 2021 was HKD53.0 million, and the specific parameters were selected by an independent qualified professional valuer as follows:

- a. Stock price: HKD3.570 per share (being the closing price of HKD3.570 per share as of the grant date)
- b. Exercise price: HKD3.570 per share (being the highest price of (i) the closing price of HKD3.570 per share as stated in the daily quotation sheets issued by the Stock Exchange on the grant date; (ii) the average closing price of HKD3.404 per share as stated in the daily quotation sheets issued by the Stock Exchange for the five (5) business days immediately preceding the grant date; and (iii) the nominal value of a share)
- c. Expected volatility: 51.35% (based on the historical share price volatility of comparable companies in the relevant period)
- d. Risk-free interest rate: 1.33% (based on the yields of HKD Hong Kong Sovereign Curve with respective tenors as at the grant date)

#### *VALUE OF SHARE OPTIONS GRANTED ON 12 NOVEMBER 2021*

The fair value of the share options granted on 12 November 2021 was HKD188.4 million, and the specific parameters were selected by an independent qualified professional valuer as follows:

- a. Stock price: HKD3.590 per share (being the closing price of HKD3.590 per share as of the grant date)
- b. Exercise price: HKD3.590 per share (being the highest price of (i) the closing price of HKD3.590 per share as stated in the daily quotation sheets issued by the Stock Exchange on the grant date; (ii) the average closing price of HKD3.546 per share as stated in the daily quotation sheets issued by the Stock Exchange for the five (5) business days immediately preceding the grant date; and (iii) the nominal value of a share)

- c. Expected volatility: 51.53% (based on the historical share price volatility of comparable companies in the relevant period)
- d. Risk-free interest rate: 1.39% (based on the yields of HKD Hong Kong Sovereign Curve with relevant tenors as at the grant date)

#### **VALUE OF SHARE OPTIONS GRANTED ON 10 DECEMBER 2021**

The fair value of the share options granted on 10 December 2021 was HKD67.9 million, and the specific parameters were selected by an independent qualified professional valuer as follows:

- a. Stock price: HKD3.800 per share (being the closing price of HKD3.800 per share as of the grant date)
- b. Exercise price: HKD3.836 per share (being the highest price of (i) the closing price of HKD3.800 per share as stated in the daily quotation sheets issued by the Stock Exchange on the grant date; (ii) the average closing price of HKD3.836 per share as stated in the daily quotation sheets issued by the Stock Exchange for the five (5) business days immediately preceding the grant date; and (iii) the nominal value of a share)
- c. Expected volatility: 51.54% (based on the historical share price volatility of comparable companies in the relevant period)
- d. Risk-free interest rate: 1.37% (based on the yields of HKD Hong Kong Sovereign Curve with relevant tenors as at the grant date)

#### **VALUE OF SHARE OPTIONS GRANTED ON 24 JANUARY 2024**

The fair value of the share options granted on 24 January 2024 was HKD172.9 million, and the specific parameters were selected by an independent qualified professional valuer as follows:

- a. Stock price: HKD1.900 per share (being the closing price of HKD1.900 per share as of the grant date)
- b. Exercise price: HKD1.950 per share (being the highest price of (i) the closing price of HKD1.900 per share as stated in the daily quotation sheets issued by the Stock Exchange on the grant date; (ii) the average closing price of HKD1.950 per share as stated in the daily quotation sheets issued by the Stock Exchange for the five (5) business days immediately preceding the grant date; and (iii) the nominal value of a share)
- c. Expected volatility: 51.10% (based on the historical share price volatility of comparable companies in the relevant period)
- d. Risk-free interest rate: 3.57% (based on the yields of HKD Hong Kong Sovereign Curve with relevant tenors as at the grant date)



## OTHER INFORMATION

### SHARE AWARD SCHEME

#### 2019 SHARE AWARD SCHEME

The Company adopted a share award scheme on 28 December 2018 which was subsequently amended by a unanimous written resolution of the Board on 29 April 2019 (the “2019 Share Award Scheme”).

On 29 September 2020, a total of 312,620,000 shares (the “2019 Granted Shares”) have been vested to certain employees of the Group, among which 81,675,000 shares have been taken up by such employees.

As at 30 June 2025, there were a total of 230,945,000 outstanding shares. The deferred payment is from employees of the Group who acquired 230,945,000 shares under the 2019 Share Award Scheme for a purchase price of HKD1.35 per share. None of these employees is a connected person of the Company as defined under the Listing Rules.

As at the date of this report, the trustee under the 2019 Share Award Scheme, namely Bank of Communications Trust Limited (the “2019 Scheme Trustee”) held 230,945,000 shares of the Company that have been granted to certain eligible participants thereunder, pending the taking up of such shares by such grantees.

Under the 2019 Share Award Scheme, the Board shall not make any further grant of award such that the total number of shares granted under such scheme will exceed 10% of the total number of issued shares as of the date of adoption of such scheme (namely 28 December 2018). Since the adoption of the 2019 Share Award Scheme up to the date of this report, a total of 312,620,000 shares have been granted under the 2019 Share Award Scheme, representing approximately 7.2% of the total number of issued shares of the Company as of the date of adoption of such scheme. The Company adopted another share award scheme on 3 March 2022 (the “2022 Share Award Scheme”). Upon adoption of the 2022 Share Award Scheme, the Board expects that no new award will be granted under the 2019 Share Award Scheme, and there were 66,224,000 shares of the Company held by the 2019 Scheme Trustee which were not granted to any eligible participants thereunder. As at the date of this report, these shares have been transferred to the trustee under the 2022 Share Award Scheme (namely, Futu Trustee Limited) which holds such shares as part of the trust fund thereunder. The 2019 Share Award Scheme is retained for the purpose of continuing holding the 2019 Granted Shares on the relevant grantees' behalf.

#### 1. OBJECTIVE OF THE 2019 SHARE AWARD SCHEME

The objectives of the 2019 Share Award Scheme are (i) to recognise and motivate the contributions by certain eligible participants and to incentivise them and retain them for the continual operation and development of the Group; (ii) to attract suitable personnel for further development of the Group; and (iii) to provide certain eligible participants with a direct economic interest in attaining a long-term relationship between the Group and certain eligible participants.

#### 2. PARTICIPANTS OF THE 2019 SHARE AWARD SCHEME AND THE BASIS OF DETERMINING THE ELIGIBILITY OF THE PARTICIPANTS

The Board may at its discretion grant shares of the Company pursuant to the 2019 Share Award Scheme (“2019 Scheme Award Shares”) to any employee and non-executive Director of the Company or any member of the Group who in the sole opinion of the Board will contribute or have contributed to any member of the Group (collectively the “2019 Scheme Selected Participants”).

### 3. MAXIMUM NUMBER OF 2019 SCHEME AWARD SHARES

Pursuant to the rules of the 2019 Share Award Scheme, the Board shall not make any further grant of 2019 Scheme Award Shares such that the total number of shares granted under the 2019 Share Award Scheme will exceed 10% of the total number of issued shares as at 28 December 2018 (the "2019 SAS Adoption Date"). The maximum number of 2019 Scheme Award Shares that may be granted under the 2019 Share Award Scheme is 433,629,120 shares. The number of 2019 Scheme Award Shares that may be granted under the scheme was 121,009,120 as at 1 January 2025 and 30 June 2025. As at the date of this report, the number of 2019 Scheme Award Shares that may be granted under the scheme was 121,009,120, representing approximately 2.61% of the total number of issued shares of the Company. Notwithstanding the above, the Board expects that no new award will be granted under the 2019 Share Award Scheme in light of the adoption of the 2022 Share Award Scheme.

There is no maximum entitlement to 2019 Scheme Award Shares stipulated for a 2019 Scheme Selected Participant under the 2019 Share Award Scheme.

### 4. AMOUNT PAYABLE FOR THE 2019 SCHEME AWARD SHARES

An offer of grant of 2019 Scheme Award Shares shall remain open for acceptance by the 2019 Scheme Selected Participants concerned for ten (10) business days from the date of the offer. In order to receive the 2019 Scheme Award Shares, the grantee shall submit to the Company the documents stipulated under the scheme and pay to the Company the amount specified in the award notice, thereafter the Company will instruct the trustee under the scheme in writing to transfer the corresponding 2019 Scheme Award Shares to the relevant grantee. The purchase price of the 2019 Scheme Award Shares would be the average price paid by the trustee under the 2019 Share Award Scheme for such purchase or subscription of such shares.

### 5. VESTING PERIOD AND CONDITIONS

All 2019 Scheme Award Shares granted have been vested and the Board does not intend to grant any further 2019 Scheme Award Shares in light of the adoption of the 2022 Share Award Scheme.

### 6. REMAINING LIFE OF THE 2019 SHARE AWARD SCHEME

The 2019 Share Award Scheme shall be valid and effective for a term of ten (10) years commencing on the 2019 SAS Adoption Date after which no further 2019 Scheme Award Shares may be offered.

The 2019 Granted Shares were granted to six employees of the Group on 29 September 2020. As at 1 January 2025 and 30 June 2025, all the 2019 Granted Shares have been vested, among which 81,675,000 2019 Granted Shares have been taken up by the grantees, and the remaining 230,945,000 2019 Granted Shares are held on behalf of the relevant grantees subject to the payment of the relevant purchase price of HKD1.35 per share. Pursuant to the conditions accepted by these employees and with the consent of the Company, the ownership of such shares has been transferred to these employees and they are obliged to pay for such shares and complete the taking up of such shares within the remaining life of the 2019 Share Award Scheme.

During the six months ended 30 June 2025, no 2019 Scheme Award Shares were granted, cancelled, lapsed or vested.

## OTHER INFORMATION

### 2022 SHARE AWARD SCHEME

On 3 March 2022, the Company adopted the 2022 Share Award Scheme, which was subsequently amended and restated pursuant to the resolutions of the board of the Company on 23 May 2025.

#### 1. OBJECTIVE OF THE 2022 SHARE AWARD SCHEME

The objectives of the 2022 Share Award Scheme are (i) to recognise and motivate the contributions by certain eligible participants and to incentivise them and retain them for the continual operation and development of the Group; (ii) to attract suitable personnel for further development of the Group; and (iii) to provide certain eligible participants with a direct economic interest in attaining a long-term relationship between the Group and certain eligible participants.

#### 2. PARTICIPANTS OF THE 2022 SHARE AWARD SCHEME AND THE BASIS OF DETERMINING THE ELIGIBILITY OF THE PARTICIPANTS

The Board may at its discretion grant shares of the Company pursuant to the 2022 Share Award Scheme ("2022 Scheme Award Shares") to (i) any employee and non-executive Director of the Company and/or any member of the Group and any related entity who, in the sole opinion of the Board, will contribute or have contributed to any member of the Group; and (ii) agents, consultants, suppliers or any other persons who provide services to any member of the Group and, in the sole opinion of the Board, will contribute or have contributed to any member of the Group (collectively the "2022 Scheme Selected Participants"). There is no service provider sublimit under the 2022 Share Award Scheme.

#### 3. MAXIMUM NUMBER OF THE 2022 SCHEME AWARD SHARES

Pursuant to the rules of the 2022 Share Award Scheme, the Board shall not make any further grant of 2022 Scheme Award Shares such that the total number of shares granted under the 2022 Share Award Scheme will exceed 10% of the total number of issued shares as at 3 March 2022 (the "2022 SAS Adoption Date"). The maximum number of 2022 Scheme Award Shares that may be granted under the Share Award Scheme is 463,003,040 shares. The number of 2022 Scheme Award Shares that may be granted under the scheme was 442,253,040 as at 1 January 2025 and 360,907,040 as at 30 June 2025.

There is no maximum entitlement to 2022 Scheme Award Shares stipulated for a 2022 Scheme Selected Participant under the 2022 Share Award Scheme.

#### 4. AMOUNT PAYABLE FOR THE 2022 SCHEME AWARD SHARES

An offer of grant of 2022 Scheme Award Shares shall remain open for acceptance by the 2022 Scheme Selected Participants concerned for ten (10) business days from the date of the offer. In order to receive the 2022 Scheme Award Shares, the grantee shall submit to the Company the documents stipulated under the scheme and pay to the Company the amount specified in the award notice, thereafter the Company will instruct the trustee under the scheme in writing to transfer the corresponding 2022 Scheme Award Shares to the relevant grantee at nil consideration.

The purchase price of each 2022 Scheme Award Shares (if any) shall be determined by the Board at the time of grant of the 2022 Scheme Award Shares under the 2022 Share Award Scheme.

Subject to the terms of the 2022 Share Award Scheme and subject to compliance with the Listing Rules, the Board may from time to time instruct the trustee of the 2022 Share Award Scheme in writing to directly or indirectly purchase shares of the Company in the market (on the exchange or off the exchange) or otherwise receive any shares of the Company or transfer from another trust under any other employee share award scheme of the Company to the trustee. Once purchased or received, the shares are to be held directly or indirectly by the trust for the benefit of the 2022 Scheme Selected Participant under the trust on and subject to the terms and conditions of the 2022 Share Award Scheme rules and trust deed.

#### 5. VESTING PERIOD AND CONDITIONS

The Board may specify any vesting period of the 2022 Scheme Award Shares, or any conditions or performance targets that must be attained by the relevant 2022 Scheme Selected Participant before any 2022 Scheme Award Shares may be transferred to and vested in the 2022 Scheme Selected Participant.

#### 6. REMAINING LIFE OF THE 2022 SHARE AWARD SCHEME

The 2022 Share Award Scheme shall be valid and effective for a term of ten (10) years commencing on 3 March 2022 after which no further 2022 Scheme Award Share may be offered. As at 30 June 2025, the remaining life of the 2022 Share Award Scheme is approximately six years and eight months.



## OTHER INFORMATION

The table below sets out the movements of the 2022 Scheme Award Shares during the period from 1 January 2025 to 30 June 2025:

Name	Date of grant	Vesting schedule	Grant price	Granted on the date of grant	Outstanding as at 1 January 2025	Vested during the six months ended 30 June 2025	Lapsed/ cancelled during the six months ended 30 June 2025	Outstanding as at 30 June 2025
Director (Note 1)	21 October 2022	5%, 10%, 15%, 20%, 25% and 25% upon completion of the Group's annual performance assessment of 2022, 2023, 2024, 2025, 2026 and 2027, respectively	—	600,000	510,000	(90,000)	—	420,000
Employees (Note 1)	21 October 2022	5%, 10%, 15%, 20%, 25% and 25% upon completion of the Group's annual performance assessment of 2022, 2023, 2024, 2025, 2026 and 2027, respectively	—	20,150,000	15,105,000	(2,182,500)	(255,000)	12,667,500
Sub-total				20,750,000	15,615,000	(2,272,500)	(255,000)	13,087,500
Employees (Note 2)	20 June 2025	20 June 2025	—	81,346,000	—	(81,346,000)	—	—
Sub-total				81,346,000	—	(81,346,000)	—	—
Total				102,096,000	15,615,000	(83,618,500)	(255,000)	13,087,500

Note 1: An aggregate of 20,150,000 2022 Scheme Award Shares were granted to 51 employees of the Group (who are neither a Director, chief executive officer or substantial shareholder of the Company nor their respective associates, nor are they the five highest paid individuals of the Company) and 600,000 2022 Scheme Award Shares were granted to one Director of the Group on 21 October 2022. The vesting of such shares is subject to the fulfilment of the conditions set out in the grant letter (including performance targets stipulated thereunder).

Such 2022 Scheme Award Shares shall be vested in the relevant participant in the following manner:

- (a) 5% of the 2022 Scheme Award Shares shall be vested in the participant upon completion of the Group's annual performance assessment for the calendar year ending 31 December 2022;
- (b) 10% of the 2022 Scheme Award Shares shall be vested in the participant upon completion of the Group's annual performance assessment for the calendar year ending 31 December 2023;
- (c) 15% of the 2022 Scheme Award Shares shall be vested in the participant upon completion of the Group's annual performance assessment for the calendar year ending 31 December 2024;
- (d) 20% of the 2022 Scheme Award Shares shall be vested in the participant upon completion of the Group's annual performance assessment for the calendar year ending 31 December 2025;
- (e) 25% of the 2022 Scheme Award Shares shall be vested in the participant upon completion of the Group's annual performance assessment for the calendar year ending 31 December 2026; and
- (f) the remaining 25% of the 2022 Scheme Award Shares shall be vested in the participant upon completion of the Group's annual performance assessment for the calendar year ending 31 December 2027.

The grantees are not required to pay any purchase price upon vesting of the awarded share. The closing price of the shares on the Stock Exchange immediately before the grant was HKD2.75 per share. The fair value of these 2022 Scheme Award Shares granted are based on the closing price of the shares on the grant date, which was HKD2.87 per share. During the six months ended 30 June 2025, 2,272,500 2022 Scheme Award Shares were vested on 26 June 2025 and the weighted average closing price of the shares on the Stock Exchange immediately before the vesting date was HKD1.97 per share.

Note 2: An aggregate of 81,346,000 2022 Scheme Award Shares were granted to 62 employees of the Group (who are neither a Director, chief executive officer or substantial shareholder of the Company nor their respective associates) on 20 June 2025. The grantees are not required to pay any purchase price upon vesting of the awarded share. The closing price of the shares on the Stock Exchange immediately before the grant was HKD1.85 per share. The fair value of these 2022 Scheme Award Shares granted are based on the closing price of the shares on the grant date, which was HKD2.04 per share. During the six months ended 30 June 2025, 81,346,000 2022 Scheme Award Shares were vested on the same date of the grant, and the weighted average closing price of the shares on the Stock Exchange immediately before the vesting date was HKD1.85 per share.

As at 30 June 2025, the ratio of the number of shares that may be issued in respect of options and awards granted under all share schemes adopted by the Company (i.e. 93,650,500) to the weighted average number of issued shares as at 30 June 2025 (i.e. 4,631,162,400) was approximately 2.02%.

During the six months ended 30 June 2025, save as disclosed above, (i) there was no participant with share options or awards granted or to be granted by the Company in excess of the 1% individual limit (as defined under Chapter 17 of the Listing Rules); (ii) there was no service provider with share options or awards granted or to be granted by the Company exceeding 0.1% of the total issued shares of the Company in any 12-month period; and (iii) the Company have not granted any share options or awards to any related entity participants or service providers.

## OTHER INFORMATION

### INTERIM DIVIDEND

The Directors did not recommend the payment of any interim dividend for the six months ended 30 June 2025 (corresponding period of 2024: nil).

### DIRECTOR'S RIGHTS TO ACQUIRE SHARES OR DEBENTURES

Apart from the details as disclosed under the section headed "DIRECTORS' AND CHIEF EXECUTIVES' INTERESTS AND SHORT POSITIONS IN SHARES, UNDERLYING SHARES AND DEBENTURES OF THE COMPANY OR ITS ASSOCIATED CORPORATIONS" above, at no time during the six months ended 30 June 2025 were rights to acquire benefits by means of the acquisition of shares in or debentures of the Company granted to any Director or their respective spouse or children under 18 years of age, or were any such rights exercised by them; or was the Company and any of its subsidiaries a party to any arrangement to enable the Directors, or their respective spouse or children under 18 years of age, to acquire such rights in any other body corporate.

### PURCHASE, SALE OR REDEMPTION OF THE COMPANY'S LISTED SECURITIES

During the six months ended 30 June 2025, there were no purchase, sales or redemptions of the Company's listed securities by the Company or any of its subsidiaries.

### SUFFICIENCY OF THE PUBLIC FLOAT

Based on the information publicly available to the Company and to the best knowledge, information and belief of the Directors, the Directors confirm that the Company had maintained a sufficient public float as required under the Listing Rules throughout the six months ended 30 June 2025.

### DISCLOSURE OF INFORMATION

The interim report of the Group for the six months ended 30 June 2025 containing all the relevant information required by the Listing Rules has been published on the websites of The Stock Exchange of Hong Kong Limited (<http://www.hkexnews.hk>) and the Company (<http://www.lifetechmed.com>).

On behalf of the Board

**XIE Yuehui**

*Executive Director, Chairman and Chief Executive Officer*

Hong Kong, 29 August 2025

# CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

For the six months ended 30 June 2025

The Board is pleased to announce the unaudited condensed consolidated results of the Group for the six months ended 30 June 2025 together with the comparative figures for the corresponding period of 2024 and the relevant explanatory notes as set out below.

		Six months ended 30 June	
	NOTES	2025 RMB'000 (Unaudited)	2024 RMB'000 (Unaudited)
Revenue	4	676,707	652,831
Cost of sales		(178,952)	(137,447)
Gross profit		497,755	515,384
Other income, expenses, gains and losses	5	50,365	49,125
Selling and distribution expenses		(250,905)	(149,983)
Administration expenses		(118,369)	(72,594)
Research and development expenses		(114,459)	(139,926)
Operating profit		64,387	202,006
Finance income, net		10,122	8,004
Share of gains (losses) of associates		5,291	(1,365)
Profit before tax	6	79,800	208,645
Income tax expense	7	(38,035)	(22,837)
Profit for the period		41,765	185,808
Other comprehensive income (expense):			
<i>Items that will not be reclassified to profit or loss:</i>			
Fair value gain (loss) and exchange differences on investments in equity instruments at FVTOCI, net of tax		26,311	(93,036)
<i>Items that may be reclassified subsequently to profit or loss:</i>			
Exchange differences arising on translation of foreign operations		(614)	(169)
Other comprehensive income (expense) for the period		25,697	(93,205)
Total comprehensive income for the period		67,462	92,603
Profit (loss) for the period attributable to:			
Owners of the Company		55,074	205,557
Non-controlling interests		(13,309)	(19,749)
		41,765	185,808
Total comprehensive income (expense) attributable to:			
Owners of the Company		80,771	112,352
Non-controlling interests		(13,309)	(19,749)
		67,462	92,603
Earnings per share	9		
– Basic		RMB1.3 cents	RMB4.6 cents
– Diluted		RMB1.3 cents	RMB4.6 cents

# CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

As at 30 June 2025

	NOTES	30 June 2025 RMB'000 (Unaudited)	31 December 2024 RMB'000 (Audited)
<b>Non-current assets</b>			
Property, plant and equipment	10	931,071	931,036
Right-of-use assets	11	43,875	45,468
Investment properties		288,272	292,994
Intangible assets	10	763,318	730,661
Interests in associates	12	210,118	72,692
Financial assets at FVTPL	13	262,018	252,149
Equity instruments at FVTOCI	14	43,410	17,099
Deposits for acquisition of property, plant and equipment		20,260	26,964
Deferred tax assets		118,053	117,142
Fixed bank deposits		80,000	80,000
		<b>2,760,395</b>	<b>2,566,205</b>
<b>Current assets</b>			
Inventories		493,559	532,398
Trade receivables	15	205,212	136,690
Other receivables and prepayments	16	479,543	478,222
Financial assets at FVTPL	13	441,000	311,000
Fixed bank deposits		171,367	205,133
Restricted bank deposits		—	4,975
Cash and cash equivalents		782,609	665,755
		<b>2,573,290</b>	<b>2,334,173</b>
<b>Current liabilities</b>			
Trade and other payables	17	841,265	758,212
Contract liabilities		95,515	21,435
Tax liabilities		53,423	32,204
Lease liabilities		3,059	3,787
		<b>993,262</b>	<b>815,638</b>
<b>Net current assets</b>		<b>1,580,028</b>	<b>1,518,535</b>
<b>Total assets less current liabilities</b>		<b>4,340,423</b>	<b>4,084,740</b>



## CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

As at 30 June 2025

	NOTES	30 June 2025 RMB'000 (Unaudited)	31 December 2024 RMB'000 (Audited)
<b>Non-current liabilities</b>			
Government grants	18	44,298	49,793
Lease liabilities		849	1,192
Financial liabilities at FVTPL	19	558,326	558,326
		<b>603,473</b>	609,311
<b>Net assets</b>		<b>3,736,950</b>	3,475,429
<b>Capital and reserves</b>			
Share capital	20	37	37
Reserves		3,770,162	3,494,470
Equity attributable to owners of the Company		3,770,199	3,494,507
Non-controlling interests		(33,249)	(19,078)
<b>Total equity</b>		<b>3,736,950</b>	3,475,429

# CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

For the six months ended 30 June 2025

	Share capital RMB'000	Share premium RMB'000	Other reserve RMB'000	Translation reserve RMB'000	Statutory surplus reserve RMB'000 (Note i)	Investment valuation reserve RMB'000	Capital reserve RMB'000	Contribution reserve RMB'000 (Note ii)	Share option reserve RMB'000	Reserve for share award schemes RMB'000	Accumulated profits RMB'000	Total RMB'000	Non-controlling interests RMB'000	Total equity RMB'000
At 1 January 2024 (audited)	37	1,642,818	2,780	2,272	50,207	(30,348)	(3)	32,531	304,817	(287,112)	1,652,243	3,370,242	(46,272)	3,323,970
Profit (loss) for the period	—	—	—	—	—	—	—	—	—	—	205,557	205,557	(19,749)	185,808
Other comprehensive expense for the period	—	—	—	(169)	—	(93,036)	—	—	—	—	—	(93,205)	—	(93,205)
Total comprehensive (expense) income for the period	—	—	—	(169)	—	(93,036)	—	—	—	—	205,557	112,352	(19,749)	92,603
Capital contribution by non-controlling interest of subsidiaries	—	—	—	—	—	—	—	—	—	—	—	—	27,823	27,823
Recognition of equity-settled share-based payments	—	—	—	—	—	—	—	—	84,115	—	—	84,115	6,014	90,129
Exercise of share options	—	611	—	—	—	—	—	—	(238)	—	—	373	—	373
Exercise of scheme awarded shares	—	(1,631)	—	—	—	—	—	—	(4,172)	5,803	—	—	—	—
Purchase of ordinary shares	—	—	—	—	—	—	—	—	—	(146,636)	—	(146,636)	—	(146,636)
Transfer of purchased ordinary shares	—	—	—	—	—	—	—	—	—	2,014	—	2,014	—	2,014
At 30 June 2024 (unaudited)	37	1,641,798	2,780	2,103	50,207	(123,384)	(3)	32,531	384,522	(425,931)	1,857,800	3,422,460	(32,184)	3,390,276
At 1 January 2025 (audited)	37	1,632,481	3,646	1,724	50,207	(126,848)	(3)	32,531	458,219	(432,118)	1,874,631	3,494,507	(19,078)	3,475,429
Profit (loss) for the period	—	—	—	—	—	—	—	—	—	—	55,074	55,074	(13,309)	41,765
Other comprehensive (expense) income for the period	—	—	—	(614)	—	26,311	—	—	—	—	—	25,697	—	25,697
Total comprehensive (expense) income for the period	—	—	—	(614)	—	26,311	—	—	—	—	55,074	80,771	(13,309)	67,462
Acquisition of a non-wholly control subsidiary	—	—	—	—	—	—	—	—	—	—	—	—	(3,323)	(3,323)
Recognition of equity-settled share-based payments	—	—	—	—	—	—	—	—	49,495	148,198	—	197,693	2,461	200,154
Exercise of share options	—	2,316	—	—	—	—	—	—	(830)	—	—	1,486	—	1,486
Exercise of scheme awarded shares	—	(1,849)	—	—	—	—	—	—	(5,948)	7,797	—	—	—	—
Transfer of purchased ordinary shares	—	—	—	—	—	—	—	—	—	(4,393)	—	(4,393)	—	(4,393)
Share of reserve of an associate	—	—	135	—	—	—	—	—	—	—	—	135	—	135
At 30 June 2025 (unaudited)	37	1,632,948	3,781	1,110	50,207	(100,537)	(3)	32,531	500,936	(280,516)	1,929,705	3,770,199	(33,249)	3,736,950

Notes:

- Statutory surplus reserve is non-distributable and the transfer to this reserve is determined according to the relevant laws in the PRC and by the board of directors of the PRC subsidiaries in accordance with the Article of Association of the subsidiaries. Statutory surplus reserve can be used to make up for previous years' losses or convert into additional capital of the PRC subsidiaries of the Company.
- Contribution reserve represents the difference between the fair value of the consideration paid for the acquisition of Lifetech Shenzhen from shareholders and the carrying amount of the share of net assets acquired in August 2006 and it is regarded as a deemed contribution from shareholders under merger accounting.

# CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

For the six months ended 30 June 2025

	Six months ended 30 June	
	2025 RMB'000 (Unaudited)	2024 RMB'000 (Unaudited)
<b>OPERATING ACTIVITIES</b>		
Cash generated from operations	409,000	144,319
Income taxes paid	(17,727)	(41,649)
<b>NET CASH FROM OPERATING ACTIVITIES</b>	<b>391,273</b>	<b>102,670</b>
<b>INVESTING ACTIVITIES</b>		
Purchase of property, plant and equipment	(21,762)	(181,169)
Payments for intangible assets	(44)	(757)
Expenditure incurred and capitalised as intangible assets	(34,894)	(35,498)
Government grants received for acquisition of plant and equipment	—	4,200
Interest received from bank deposits	10,257	8,886
Proceeds from disposal of financial assets at FVTPL	311,000	120,000
Purchase of financial assets at FVTPL	(441,000)	(148,000)
Placement of fixed bank deposits	(100,432)	(110,912)
Decrease in restricted bank deposits	4,975	—
Release of fixed bank deposits	134,198	140,000
Acquisition of a non-wholly control subsidiary	(3,323)	—
Proceeds on partial disposal of an associate	—	2,920
Capital contribution to associates	(132,000)	(24,000)
<b>NET CASH USED IN INVESTING ACTIVITIES</b>	<b>(273,025)</b>	<b>(224,330)</b>
<b>FINANCING ACTIVITIES</b>		
Bank borrowing raised	—	99,000
Interest paid for bank borrowing	—	(658)
Capital contributed by non-controlling interests of subsidiaries	—	27,823
Purchase of shares under share award schemes	—	(146,636)
Proceeds from issue of shares upon exercise of share options	1,486	373
Repayments of lease liabilities	(2,131)	(4,584)
Repayments of Interest on lease liabilities	(135)	(224)
<b>NET CASH USED IN FINANCING ACTIVITIES</b>	<b>(780)</b>	<b>(24,906)</b>
<b>NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</b>	<b>117,468</b>	<b>(146,566)</b>
<b>CASH AND CASH EQUIVALENTS AT BEGINNING OF THE PERIOD</b>	<b>665,755</b>	<b>979,312</b>
<b>EFFECT OF FOREIGN EXCHANGE RATE CHANGES</b>	<b>(614)</b>	<b>(169)</b>
<b>CASH AND CASH EQUIVALENTS AT END OF THE PERIOD,</b> representing bank balances and cash	<b>782,609</b>	<b>832,577</b>

# NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the six months ended 30 June 2025

## 1. GENERAL INFORMATION

The Company was incorporated in the Cayman Islands on 17 August 2006 as an exempted company with limited liability and its shares are listed on the Main Board of the Stock Exchange. Mr. Xie Yuehui, is the Chairman and Chief Executive Officer of the Company. The address of the registered office is PO Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands and the address of the principal place of business is LifeTech Scientific Building, No.22, Keji 12th Road South, High-tech Industrial Park, Nanshan District, Shenzhen, Guangdong Province, the PRC.

The Company is an investment holding company. The principal activities of the Group are developing, manufacturing and trading of advanced interventional medical devices for cardiovascular and peripheral vascular diseases and disorders.

The condensed consolidated financial statements are presented in Renminbi, which is the functional currency of the Company and the Group's major operating subsidiaries.

## 2. BASIS OF PREPARATION

The unaudited condensed consolidated financial statements of the Group for the six months ended 30 June 2025 have been prepared in accordance with International Accounting Standard 34 "Interim Financial Reporting" issued by the International Accounting Standards Board ("IASB") as well as with the applicable disclosure requirements of Appendix D2 to the Listing Rules.

## 3. PRINCIPAL ACCOUNTING POLICIES

The condensed consolidated financial statements have been prepared on the historical cost basis except for certain financial instruments, which are measured at fair value.

The accounting policies and methods of computation used in the condensed consolidated financial statements for the six months ended 30 June 2025 are consistent with those followed in the preparation of the Group's annual financial statements for the year ended 31 December 2024.

In addition, in the current interim period, the Group has applied, for the first time, a new interpretation and certain amendments to International Financial Reporting Standards ("IFRSs") issued by the IASB that are mandatorily effective for the current interim period. The application of the above new interpretation and amendments to IFRSs in the current interim period has had no material effect on the amounts reported in these condensed consolidated financial statements and/or disclosures set out in these condensed consolidated financial statements.

## 4. SEGMENT INFORMATION

The segment information reported internally was analysed on the basis of their products supplied by the Group's operating divisions which is consistent with the internal information that is regularly reviewed by executive Directors of the Company, the chief operating decision makers, for the purposes of resource allocation and assessment of performance.

## NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the six months ended 30 June 2025

### 4. SEGMENT INFORMATION - CONTINUED

The Group's operating segments under IFRSs 8 are as follows:

- Structural heart diseases business: trade, manufacture, research and development of devices related to structural heart diseases.
- Peripheral vascular diseases business: trade, manufacture, research and development of devices related to peripheral vascular diseases.
- Cardiac pacing and electrophysiology business: trade, manufacture, research and development of devices related to cardiac pacing and electrophysiology.

Information regarding the above segments is reported below.

#### [A] SEGMENT REVENUE AND RESULTS

The following is an analysis of the Group's revenue and results by operating and reportable segments:

**For the six months ended 30 June 2025**

	Structural heart diseases business RMB'000 (Unaudited)	Peripheral vascular diseases business RMB'000 (Unaudited)	Cardiac pacing and electrophysiology business RMB'000 (Unaudited)	Total RMB'000 (Unaudited)
<b>SEGMENT REVENUE</b>				
External sales	271,539	391,693	13,475	676,707
Segment profit	237,686	258,214	1,855	497,755
Unallocated income				
– Other income and other gains				63,730
– Finance income				10,257
– Share of gains of associates				5,291
Unallocated expense				
– Selling and distribution expenses				(250,905)
– Administration expenses				(118,369)
– Research and development expenses				(114,459)
– Other expenses and losses				(13,365)
– Finance costs				(135)
Profit before tax				79,800



## NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the six months ended 30 June 2025

### 4. SEGMENT INFORMATION - CONTINUED

#### [A] SEGMENT REVENUE AND RESULTS - CONTINUED

For the six months ended 30 June 2024

	Structural heart diseases business RMB'000 (Unaudited)	Peripheral vascular diseases business RMB'000 (Unaudited)	Cardiac pacing and electrophysiology business RMB'000 (Unaudited)	Total RMB'000 (Unaudited)
<b>SEGMENT REVENUE</b>				
External sales	271,250	380,725	856	652,831
Segment profit (losses)	243,166	285,320	(13,102)	515,384
Unallocated income				
– Other income and other gains				76,135
– Finance income				8,886
Unallocated expense				
– Selling and distribution expenses				(149,983)
– Administration expenses				(72,594)
– Research and development expenses				(139,926)
– Other expenses and losses				(27,010)
– Finance costs				(882)
– Share of losses of associates				(1,365)
Profit before tax				208,645

Segment profit represents the gross profit earned by each segment without allocation of all other items of income and expenses, as set out above. This is the measure reported to the chief operating decision makers, the executive Directors of the Company, for the purposes of resources allocation and assessment of segment performance.

## NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the six months ended 30 June 2025

### 4. SEGMENT INFORMATION - CONTINUED

#### (B) SEGMENT ASSETS AND LIABILITIES

The following is an analysis of the Group's assets and liabilities by operating and reportable segments:

##### SEGMENT ASSETS

	30 June 2025 RMB'000 (Unaudited)	31 December 2024 RMB'000 (Audited)
Operating segments:		
Structural heart diseases business	768,334	688,026
Peripheral vascular diseases business	1,108,398	979,544
Cardiac pacing and electrophysiology business	53,239	70,595
Total segment assets	1,929,971	1,738,165
Unallocated assets		
Interests in associates	210,118	72,692
Property, plant and equipment	413,127	542,596
Right-of-use assets	43,875	45,468
Investment properties	288,272	292,994
Deferred tax assets	118,053	117,142
Financial assets at FVTPL	703,018	563,149
Equity instruments at FVTOCI	43,410	17,099
Other receivables and prepayments	479,543	478,222
Cash and cash equivalents	782,609	665,755
Restricted bank deposits	—	4,975
Fixed bank deposits	251,367	285,133
Intangible assets	50,062	50,024
Deposits for acquisition of property, plant and equipment	20,260	26,964
Consolidated assets	5,333,685	4,900,378

## NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the six months ended 30 June 2025

### 4. SEGMENT INFORMATION - CONTINUED

#### (B) SEGMENT ASSETS AND LIABILITIES - CONTINUED

##### SEGMENT LIABILITIES

	30 June 2025 RMB'000 (Unaudited)	31 December 2024 RMB'000 (Audited)
Operating segments:		
Structural heart diseases business	172,333	127,440
Peripheral vascular diseases business	248,607	181,439
Cardiac pacing and electrophysiology business	28,525	22,733
Total segment liabilities	449,465	331,612
Unallocated liabilities		
Other payables	483,235	443,377
Lease liabilities	3,908	4,979
Tax liabilities	53,423	32,204
Government grants	48,378	54,451
Financial liabilities at FVTPL	558,326	558,326
Consolidated liabilities	1,596,735	1,424,949

For the purposes of monitoring segment performances and allocating resources between segments:

- All assets are allocated to operating segments other than interests in associates, certain property, plant and equipment, right-of-use assets, investment properties, deferred tax assets, financial assets at FVTPL, equity instruments at FVTOCI, other receivables and prepayments, cash and cash equivalents, fixed bank deposits, restricted bank deposits, certain intangible assets and deposits for acquisition of property, plant and equipment; and
- All liabilities are allocated to operating segments in arriving at segment liabilities, which exclude certain other payables, tax liabilities, government grants (include current portion under other payables and non-current portion), lease liabilities and financial liabilities at FVTPL.

## NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the six months ended 30 June 2025

### 5. OTHER INCOME, EXPENSES, GAINS AND LOSSES

	Six months ended 30 June	
	2025 RMB'000 (Unaudited)	2024 RMB'000 (Unaudited)
Other income and expenses		
Government grants	7,989	7,941
Rental income generated from investment properties	17,712	17,097
Depreciation of investment properties	(4,722)	(4,397)
Others	(4,246)	(1,831)
	<b>16,733</b>	<b>18,810</b>
Other gains and losses		
Losses on disposal of property, plant and equipment and intangible assets	(269)	—
Gains (losses) from changes in fair value of hybrid funds	13,996	(18,243)
(Losses) gains from changes in fair value of equity funds	(3,260)	50,163
Unrealised foreign exchange (losses) gains in financial assets at FVTPL	(868)	934
Other net foreign exchange gains (losses)	24,033	(2,539)
	<b>33,632</b>	<b>30,315</b>
	<b>50,365</b>	<b>49,125</b>

## NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the six months ended 30 June 2025

### 6. PROFIT BEFORE TAX

	Six months ended 30 June	
	2025 RMB'000 (Unaudited)	2024 RMB'000 (Unaudited)
Profit before tax has been arrived at after charging (crediting):		
Staff costs, including Directors' remuneration		
Directors' fees	360	360
Salaries, wages, performance related bonus and other benefits	168,296	168,356
Share-based payment expenses	193,500	61,325
Retirement benefits scheme contributions	18,658	18,032
Less: capitalised in development costs, construction in progress and inventories	(21,238)	(19,849)
	<b>359,576</b>	<b>228,224</b>
Cost of inventories recognised as expenses	178,952	137,447
Depreciation of property, plant and equipment	26,415	25,562
Depreciation of right-of-use assets	2,678	4,989
Depreciation of investment properties	4,722	4,397
Amortisation of intangible assets	8,935	6,828
Total depreciation and amortisation	<b>42,750</b>	<b>41,776</b>
Gross rental income from investment properties	(17,712)	(17,097)
Less: direct operating expenses incurred for investment properties that generated rental income during the period	4,722	4,397
	<b>(12,990)</b>	<b>(12,700)</b>



## NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the six months ended 30 June 2025

### 7. INCOME TAX EXPENSE

	Six months ended 30 June	
	2025 RMB'000 (Unaudited)	2024 RMB'000 (Unaudited)
Current tax charge:		
PRC Enterprise Income Tax ("PRC EIT")	30,415	34,210
Hong Kong Profits Tax	8,530	8,059
Deferred tax credit:		
Current period	(910)	(19,432)
	<b>38,035</b>	<b>22,837</b>

The Company is tax exempted under the laws of the Cayman Islands.

Lifetech Scientific International Holding Limited, a subsidiary of the Company, is subject to Hong Kong Profits Tax. On 21 March 2018, the Hong Kong Legislative Council passed The Inland Revenue (Amendment) (No. 7) Bill 2018 (the "Bill") which introduced the two-tiered profits tax rates regime. The Bill was signed into law on 28 March 2018 and was gazetted on the following day. Under the two-tiered profits tax rates regime, the first HKD2.0 million of profits of the qualifying group entity will be taxed at 8.25%, and profits above HKD2.0 million will be taxed at 16.5%. The profits of group entities not qualifying for the two-tiered profits tax rates regime will continue to be taxed at a flat rate of 16.5% on assessable profits earned in Hong Kong.

Under the Law of the PRC on Enterprise Income Tax (the "EIT Law") and Implementation Regulation of the EIT Law, the tax rate of the PRC subsidiaries is 25% except for Lifetech Shenzhen, the major operating subsidiary in the PRC. Lifetech Shenzhen has been qualified as a High and New Technology Enterprise since 2009, which was subsequently renewed in November 2023, and therefore Lifetech Shenzhen is entitled to a preferential corporate income tax rate of 15% for the periods ended 30 June 2025 and 2024.

The applicable income tax rate of Lifetech Scientific India Private Ltd. in the jurisdiction of India is 30.9% on its taxable profits. No provision for taxation in India has been made as there is no assessable profits in India for both periods.

Taxation arising in other jurisdictions is calculated at the rates prevailing in the relevant jurisdictions.

### 8. DIVIDENDS

No dividend was paid, declared or proposed during the interim periods ended 30 June 2025 and 2024, nor has any dividend been proposed since the end of the Reporting Period.

## NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the six months ended 30 June 2025

### 9. EARNINGS PER SHARE

The calculation of basic and diluted earnings per share attributable to the owners of the Company is based on the following data:

Six months ended 30 June		
	2025 RMB'000 (Unaudited)	2024 RMB'000 (Unaudited)
<b>Earnings:</b>		
Earnings for the purposes of basic and diluted earnings per share	55,074	205,557
Six months ended 30 June		
	2025 '000 (Unaudited)	2024 '000 (Unaudited)
<b>Number of shares:</b>		
Weighted average number of ordinary shares for the purpose of basic earnings per share (Note)	4,344,028	4,420,884
Effect of dilutive potential ordinary shares:		
Share options	130	12,927
Award shares	6,490	18,351
Weighted average number of ordinary shares for the purpose of diluted earnings per share (Note)	4,350,648	4,452,162

The computation of diluted earnings per share does not assume the conversion certain of the Company's share options because the exercise price of those options was higher than the average market prices for shares for the six months ended 30 June 2025 and 2024.

Note: Treasury shares are deducted from total number of shares in issue for the purpose of calculating earnings per share.

### 10. PROPERTY, PLANT AND EQUIPMENT AND INTANGIBLE ASSETS

During the six months ended 30 June 2025, the Group spent approximately RMB21,334,000 (corresponding period of 2024: approximately RMB25,393,000) for the acquisition of equipment and improvement of plant to enhance its manufacturing capabilities. In addition, the Group also incurred approximately RMB10,533,000 (corresponding period of 2024: approximately RMB127,571,000) for construction cost of the industrial park.

During the six months ended 30 June 2025, the Group incurred approximately RMB41,548,000 (corresponding period of 2024: approximately RMB64,302,000) of R&D expenditure for new products, and incurred approximately RMB44,000 (corresponding period of 2024: approximately RMB757,000) for the purchase of other intangible assets.

## NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the six months ended 30 June 2025

### 11. RIGHT-OF-USE ASSETS

	Leasehold lands RMB'000	Leased properties RMB'000	Total RMB'000
<b>As at 1 January 2025</b>			
Carrying amount (audited)	40,766	4,702	45,468
<b>For the six months ended 30 June 2025</b>			
Additions	—	1,085	1,085
Depreciation charge	(644)	(2,034)	(2,678)
<b>As at 30 June 2025</b>			
Carrying amount (unaudited)	40,122	3,753	43,875

During the six months ended 30 June 2025, the Group leases various offices, warehouses and staff dormitories. Lease contracts are entered into for fixed term of 1 month to 4 years. Lease terms are negotiated on individual basis and contain different terms. In determining the lease term and assessing the length of the non-cancellable period, the Group applies the definition of a contract and determines the period for which the contract is enforceable.

During the six months ended 30 June 2025, the short-term lease expenses were amounted to approximately RMB675,000.

In addition, lease liabilities of approximately RMB3,908,000 (31 December 2024: approximately RMB 4,979,000) are recognised with related right-of-use assets of approximately RMB3,753,000 (31 December 2024: approximately RMB4,702,000) as at 30 June 2025. The lease agreements do not impose any covenants other than the security interests in the leased properties that are held by the lessor and the relevant leased properties may not be used as security for borrowing purposes. As at 30 June 2025, the Group has no lease commitments as lessee.

### 12. INTERESTS IN ASSOCIATES

	30 June 2025 RMB'000 (Unaudited)	31 December 2024 RMB'000 (Audited)
Cost of investment in associates	212,775	80,775
Share of post-acquisition losses and other comprehensive expenses	(2,657)	(8,083)
	<b>210,118</b>	<b>72,692</b>

## NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the six months ended 30 June 2025

### 12. INTERESTS IN ASSOCIATES - CONTINUED

The following sets out the particulars of the associates of the Group as at 30 June 2025 and 31 December 2024, which in the opinion of the Directors, principally affected the results or net assets of the Group:

Name of entities	Country of incorporation	Place of business	Proportion of ownership interest held by the Group		Principle activities
			30 June 2025	31 December 2024	
深圳市先健創興天使投資合夥企業(有限合夥) (Note i)	The PRC	The PRC	40.00%	40.00%	Investing
Shenzhen High-Performance Medical Device National Research Institute Co., Ltd. (深圳高性能醫療器械國家研究院有限公司) ("Joint Laboratory") (Note ii)	The PRC	The PRC	10.42%	10.42%	Developing medical devices
Shenzhen Lifetech Cardio Medical Electronics Co., Ltd. (深圳市先健心康醫療電子有限公司) ("Shenzhen Cardio") (Note ii)	The PRC	The PRC	13.10%	13.10%	Developing, manufacturing and trading of medical devices
Shenzhen Advanced Medical Services Co., Ltd. (深圳市領先醫療服務有限公司) ("Advanced Medical") (Note iii)	The PRC	The PRC	40.00%	40.00%	Consulting and technology services
Affector Medtech (Note iii)	The PRC	The PRC	22.22%	—	Developing, manufacturing and trading of medical devices

Notes:

- (i) The Group is able to exercise significant influence over the partnership enterprise because the Group is entitled to appoint three of the seven members under its Investment Committee.
- (ii) The Group continues to be able to exercise significant influence over Joint Laboratory and Shenzhen Cardio because the Group is entitled to appoint one of the five directors under its Articles of Association.
- (iii) The Group is able to exercise the significant influence over Advanced Medical and Affector Medtech.

All of these associates are accounted for using the equity method in these consolidated financial statements. The Group considers none of its associates is individually material.

Financial information of these companies has not been disclosed since these associates are immaterial to the Group.

## NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the six months ended 30 June 2025

### 13. FINANCIAL ASSETS AT FVTPL

	30 June 2025 RMB'000 (Unaudited)	31 December 2024 RMB'000 (Audited)
Financial assets mandatorily measured at FVTPL:		
Non-current assets		
Unlisted funds		
– Equity funds (Note i)	205,302	209,430
– Hybrid funds (Note ii)	56,636	42,639
Others	80	80
	<b>262,018</b>	<b>252,149</b>
Current assets		
Short-term bank structured deposits (Note iii)	<b>441,000</b>	<b>311,000</b>

Notes:

- (i) On 25 May 2018, the Group entered into a subscription agreement with certain independent third parties pursuant to which the Group agreed to subscribe for interest of a private equity fund, as a limited partner, for an aggregate consideration of USD6,000,000 (equivalent to approximately RMB38,202,000) in cash. The 2018 Equity Fund principally invests in securities or assets of companies that are involved in the healthcare industry, with a particular focus on cross-border innovative late-stage venture opportunities and crossover investments.

On 24 October 2022, the Group entered into a subscription agreement with certain independent third parties pursuant to which the Group agreed to subscribe for interest of a private equity fund, as a limited partner, for an aggregate consideration of USD20,000,000 (equivalent to approximately RMB144,378,000) in cash. The purposes of the 2022 Equity Fund are to seek capital appreciation primarily by acquiring, holding and disposing of securities, independently or with others, primarily in non-listed or, sometimes, listed persons involved in the healthcare industry, with a particular focus on leading innovative technologies.

- (ii) On 8 January 2021, the Group entered into a contract to purchase the 2021 Hybrid Fund unit with a financial institution, which was accounted for as financial assets at FVTPL on initial recognition, for a consideration of RMB10,000,000 in cash.

On 28 November 2023, the Group entered into a contract to purchase the 2023 Hybrid Fund unit with a financial institution, which was accounted for as financial assets at FVTPL on initial recognition, for a consideration of RMB50,000,000 in cash.

- (iii) During the six months ended 30 June 2025, Lifetech Shenzhen entered into structured deposit agreements with certain banks in PRC.

The equity funds are managed by fund/investment managers, and the Group does not have rights to engage in the management of the equity funds. The Group, as a limited partner in the equity funds does not have the rights to participate in the financial and operating policy decisions of the equity funds. As such, the Group does not have significant influence over the equity funds, and therefore they are not accounted for as associates.



## NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the six months ended 30 June 2025

### 13. FINANCIAL ASSETS AT FVTPL - CONTINUED

The equity funds and hybrid funds are accounted for as financial assets at FVTPL in accordance with IFRS 9. In the opinion of the Directors of the Company, these funds are held for long-term strategic investment purposes and as such, the investments are classified as non-current assets.

The Group holds approximately 9.69% (31 December 2024: approximately 9.69%) and approximately 4.60% (31 December 2024: approximately 4.60%) interest respectively in the 2018 Equity Fund and 2022 Equity Fund as at 30 June 2025.

### 14. EQUITY INSTRUMENTS AT FVTOCI

	30 June 2025 RMB'000 (Unaudited)	31 December 2024 RMB'000 (Audited)
Listed:		
– Equity securities listed in Hong Kong (Note)	43,410	17,099

Note:

On 21 September 2022, the Group entered into a subscription agreement with Jenscare Scientific pursuant to which the Group agreed to subscribe for shares of Jenscare Scientific upon the initial public offering, as a cornerstone investor, for an aggregate consideration of USD20,000,000 (equivalent to approximately RMB143,947,000) in cash with the subscription price of HKD27.8 per share. There is a lock-up period of six months upon the initial public offering on 10 October 2022.

In the opinion of the Directors of the Company, the investment is held for long-term strategic investment purposes and as such, it is classified as non-current asset.

### 15. TRADE RECEIVABLES

The Group normally allows a credit period of 30 to 180 days (corresponding period of 2024: 30 to 180 days) to its trade customers. The following is an aged analysis of trade receivables, net of allowance for credit losses, presented based on the invoice dates at the end of the Reporting Period, which approximated the respective revenue recognition dates:

	30 June 2025 RMB'000 (Unaudited)	31 December 2024 RMB'000 (Audited)
1 - 90 days	158,755	124,812
91 - 180 days	36,504	6,616
181 - 365 days	7,328	2,760
Over 365 days	2,625	2,502
	205,212	136,690

## NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the six months ended 30 June 2025

### 16. OTHER RECEIVABLES AND PREPAYMENTS

	30 June 2025 RMB'000 (Unaudited)	31 December 2024 RMB'000 (Audited)
Other debtors (Note i)	41,110	18,823
Value added tax deductible	47,720	76,596
Prepayments	72,735	67,928
Advance to employees - interest free	29,890	22,904
Advance to employees - others (Note ii)	284,495	287,519
Rental deposits	1,826	2,874
Other deposits	1,767	1,578
	<b>479,543</b>	<b>478,222</b>

Notes:

- (i) Amounts are unsecured and interest-free. In the opinion of the directors, the Group will demand for repayments within one year from the end of the Reporting Period and the amounts are therefore considered as current.

Included in the amount as at 30 June 2025 was the balance to an associate amounting to RMB2,416,000 (31 December 2024: RMB1,775,000).

- (ii) As at 30 June 2025 and 31 December 2024, the advance to employees represents deferred payment from employees of the Group who acquired 230,945,000 shares under the Group's 2019 Share Award Scheme for a purchase price of HKD1.35 per share. The deferred payments are secured by the corresponding shares. None of these employees is a connected person of the Company as defined under the Listing Rules.

Pursuant to the conditions accepted by these employees and with the consent of the Company, the ownership of such shares has been transferred to these employees and they are obliged to pay for such shares and complete the taking up of such shares within the remaining life of the 2019 Share Award Scheme.

### 17. TRADE PAYABLES

The credit period granted by suppliers to the Group ranged from 30 to 120 days (corresponding period of 2024: 30 to 120 days). The following is an aged analysis of trade payables presented based on the invoice dates at the end of the Reporting Period:

	30 June 2025 RMB'000 (Unaudited)	31 December 2024 RMB'000 (Audited)
0 - 30 days	17,729	7,520
31 - 60 days	8,863	9,020
61 - 120 days	13,498	9,007
Over 120 days	42,908	33,996
	<b>82,998</b>	<b>59,543</b>

## NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the six months ended 30 June 2025

### 18. GOVERNMENT GRANTS

	Six months ended 30 June	
	2025 RMB'000 (Unaudited)	2024 RMB'000 (Unaudited)
Government grant related to assets:		
At the beginning of the period	54,451	45,678
Additions	—	4,200
Released to profit or loss	(6,073)	(2,575)
At the end of the period	48,378	47,303
	30 June 2025 RMB'000 (Unaudited)	31 December 2024 RMB'000 (Audited)
Classified as:		
Current liabilities (included in other payables)	4,080	4,658
Non-current liabilities	44,298	49,793
	48,378	54,451

Government grants include subsidies in relation to the acquisition of plant, equipment and the research and development of medical devices. The amount will transfer to income on a systematic basis over the estimated useful lives of the related assets.

During the six months ended 30 June 2025, the Group recognised income of approximately RMB7,989,000 (corresponding period of 2024: approximately RMB7,941,000) of which approximately RMB1,916,000 (corresponding period of 2024: approximately RMB5,366,000) was received and directly recognised in profit or loss.

## NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the six months ended 30 June 2025

### 19. FINANCIAL LIABILITIES AT FVTPL

	30 June 2025 RMB'000 (Unaudited)	31 December 2024 RMB'000 (Audited)
Capital injection from other investors	558,326	558,326

During the year ended 31 December 2020, Lifetech Shenzhen, a wholly-owned subsidiary of the Company, entered into Series A Agreement with certain independent third parties for issuance of shares of Biotyx Medical, a subsidiary of Lifetech Shenzhen, with a total consideration of RMB135,000,000. Pursuant to the Series A Agreement, during the year ended 31 December 2020, Biotyx Medical received the first capital injection of RMB67,500,000. During the year ended 31 December 2021, Biotyx Medical received the second capital injection of RMB67,500,000. Upon the completion of the above transaction, the Group's equity interest in Biotyx Medical decreased from 66.17% to 57.44%.

During the year ended 31 December 2023, Lifetech Shenzhen entered into Series B Agreement with certain independent third parties for issuance of shares of Biotyx Medical, with a total consideration of RMB202,000,000. Pursuant to the Series B Agreement, during the year ended 31 December 2023, Biotyx Medical received the total capital injection of RMB202,000,000. Upon the completion of the above transaction, the Group's equity interest in Biotyx Medical decreased from 57.44% to 49.64%.

Pursuant to the above mentioned Series A and Series B Agreements, if Biotyx Medical is unable to meet certain specified conditions under agreed timeframe, the holders of these shares will have the right to require Biotyx Medical to redeem all of their shares at the predetermined consideration. Accordingly, these shares are classified as a financial liability.

### 20. SHARE CAPITAL

	Number of Shares	Amount USD
<b>Ordinary Shares</b>		
<b>Authorised:</b>		
At 1 January 2024, 31 December 2024 and 30 June 2025 at USD0.00000125 each	40,000,000,000	50,000

## NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the six months ended 30 June 2025

### 20. SHARE CAPITAL - CONTINUED

	Number of Shares	Amount USD	Shown in the condensed consolidated financial statements as RMB'000
<b>Issued and fully paid:</b>			
At 1 January 2024	4,630,232,400	5,789	37
Exercise of share options	380,000	— <sup>#</sup>	— <sup>*</sup>
At 31 December 2024	4,630,612,400	5,789	37
Exercise of share options	1,100,000	1	— <sup>*</sup>
<b>At 30 June 2025</b>	<b>4,631,712,400</b>	<b>5,790</b>	<b>37</b>

\* Less than RMB1,000.

# Less than USD1.

### 21. SHARE-BASED PAYMENT TRANSACTIONS

#### (A) SHARE OPTION SCHEME

##### *EQUITY-SETTLED SHARE OPTION SCHEME OF THE COMPANY:*

The Previous Scheme adopted by the Company on 22 October 2011 which was amended by a unanimous written resolution of the Board on 5 May 2015 was terminated pursuant to an ordinary resolution passed by the shareholders at the EGM on 17 September 2021, and the shares already granted are still effective until the end of the exercisable period. A new Share Option Scheme in place of the Previous Scheme was adopted by the Company with effect from 17 September 2021 which has a term of 10 years.



## NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the six months ended 30 June 2025

### 21. SHARE-BASED PAYMENT TRANSACTIONS - CONTINUED

#### [A] SHARE OPTION SCHEME - CONTINUED

##### *EQUITY-SETTLED SHARE OPTION SCHEME OF THE COMPANY: - CONTINUED*

The terms, conditions and fair values at the grant date of the grants are as follows:

	Number of options	Fair value HKD	Weighted average exercise price HKD	Weighted average fair value per share option HKD
Options granted to executives, Directors and employees on:				
on 5 May 2015	160,000,000	132,338,000	1.4640	0.8271
on 31 March 2021	33,320,000	53,044,000	3.5700	1.5920
on 12 November 2021	101,800,000	188,423,000	3.5900	1.8509
on 10 December 2021	11,000,000	21,350,000	3.8360	1.9409
on 24 January 2024	174,750,000	172,908,000	1.9500	0.9895
	<u>480,870,000</u>	<u>568,063,000</u>		
Options granted to consultants on 10 December 2021 (Note)	24,000,000	46,581,000	3.8360	1.9409

Note: These consultants perform services that are similar to services currently provided by employees.

The above share options are vested in instalments over an explicit vesting period of 12 months to 5.5 years.

## NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the six months ended 30 June 2025

### 21. SHARE-BASED PAYMENT TRANSACTIONS - CONTINUED

#### [A] SHARE OPTION SCHEME - CONTINUED

##### *EQUITY-SETTLED SHARE OPTION SCHEME OF THE COMPANY: - CONTINUED*

The number and weighted average exercise prices of share options under the Previous Scheme and the Share Option Scheme are as follows:

	Six months ended 30 June			
	2025		2024	
	Weighted average exercise price HKD	Number of options	Weighted average exercise price HKD	Number of options
Outstanding at the beginning of the period	2.5082	389,204,600	2.9650	225,407,600
Granted during the period	—	—	1.9500	174,750,000
Exercised during the period	1.4640	(1,100,000)	1.4640	(280,000)
Lapsed during the period (Note)	1.6043	(76,077,100)	3.5463	(2,603,000)
Outstanding as at the end of the period	2.7323	312,027,500	2.5158	397,274,600
Exercisable as at the end of the period	3.1980	93,650,500	2.3945	123,078,600

Note: During the period, certain employees resigned or failed to pass the performance assessment and respective share options were lapsed accordingly; and certain share options were lapsed due to expiration.

All the share options granted are exercisable by the grantees upon vesting.

For the six months ended 30 June 2025, the Group recognised approximately RMB33,377,000 (corresponding period of 2024: approximately RMB40,626,000) share-based payment expenses in profit or loss in relation to the Previous Scheme and the Share Option Scheme. In addition, approximately RMB1,329,000 (corresponding period of 2024: approximately RMB1,481,000) was capitalised in development costs.

##### *EQUITY-SETTLED SHARE OPTION SCHEME OF BIOTYX MEDICAL:*

Biotyx Medical adopted a share option scheme (the "Biotyx Medical Scheme"), of which to enable Biotyx Medical to grant options to directors, supervisors, senior management, other management personnel, key employees and business partner, who have contributed or may contribute to the development and growth of Biotyx Medical and/or any entity in which Biotyx Medical holds an equity interest.

## NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the six months ended 30 June 2025

### 21. SHARE-BASED PAYMENT TRANSACTIONS - CONTINUED

#### [A] SHARE OPTION SCHEME - CONTINUED

##### *EQUITY-SETTLED SHARE OPTION SCHEME OF BIOTYX MEDICAL: - CONTINUED*

The following table discloses movements of the Biotyx Medical Scheme during the six months ended 30 June 2025 and 2024:

	Six months ended 30 June			
	2025		2024	
	Weighted average exercise price RMB	Number of options	Weighted average exercise price RMB	Number of options
Outstanding at the beginning of the period	0.2547	11,485,500	0.2547	12,015,600
Exercised during the period	—	—	—	—
Lapsed during the period	0.2547	(824,600)	0.2547	(530,100)
Outstanding as at the end of the period	0.2547	10,660,900	0.2547	11,485,500
Exercisable as at the end of the period	0.2547	10,660,900	0.2547	9,335,650

Details of specific categories of share options under the Biotyx Medical Scheme are as follows:

#### Granted on 1 November 2023

Types	Vesting period	Exercisable period	Grant date fair value per option RMB
Batch I	N/A	1 November 2023 - 1 November 2028	22.4467
Batch II	N/A	1 November 2023 - 1 November 2028	22.4467
Batch III	3 months	31 January 2024 - 31 January 2029	22.4467
Batch IV	3 months	31 January 2024 - 31 January 2029	22.4467
Batch V	15 months	31 January 2025 - 31 January 2030	22.4467

Fair value of share options granted

RMB269,711,000

The fair value of shares granted was measured by reference to the price at which third party investors made contributions to Biotyx Medical in 2023.

## NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the six months ended 30 June 2025

### 21. SHARE-BASED PAYMENT TRANSACTIONS - CONTINUED

#### [A] SHARE OPTION SCHEME - CONTINUED

##### *EQUITY-SETTLED SHARE OPTION SCHEME OF BIOTYX MEDICAL: - CONTINUED*

For the six months ended 30 June 2025, the Group recognised approximately RMB335,000 (corresponding period of 2024: approximately RMB11,585,000) share-based payment expenses in profit or loss in relation to the Biotyx Medical Scheme. In addition, approximately RMB4,551,000 (corresponding period of 2024: approximately RMB26,763,000) was capitalised in development costs.

#### [B] SHARE AWARD SCHEME

##### *EQUITY-SETTLED SHARE AWARD SCHEME OF THE COMPANY*

The 2019 Share Award Scheme

On 28 December 2018, the Company adopted the 2019 Share Award Scheme which was subsequently amended by unanimous written resolutions of the Board on 29 April 2019.

The 2019 Share Award Scheme shall be valid and effective for a term of 10 years commencing on 28 December 2018 after which no further 2019 Scheme Award Shares may be offered.

As at 31 December 2023, the remaining shares have been issued to such grantees and there are no outstanding shares under the 2019 Share Award Scheme.

For the six months ended 30 June 2025 and 2024, the Group has not recognised any expenses in the profit or loss.

The 2022 Share Award Scheme

On 3 March 2022, the Company adopted 2022 Share Award Scheme, which was subsequently amended and restated pursuant to the resolutions of the board of the Company on 23 May 2025.

The 2022 Share Award Scheme shall be valid and effective for a term of 10 years commencing on 3 March 2022 after which no further 2022 Scheme Award Shares may be offered.

During the six months ended 30 June 2024, the Company instructed the Futu Trustee Limited to repurchase an aggregate of 101,780,000 ordinary shares at a consideration of RMB146,637,000 in accordance with the 2022 Share Award Scheme.

On 21 October 2022, a total of 20,750,000 shares of the Company have been granted by the Company to certain senior management/employees at no cost and the vesting period under the 2022 Share Award Scheme ranges from six months to six years.

On 20 June 2025, a total of 81,346,000 shares of the Company have been granted by the Company to certain senior management/employees at no cost and were vested on the same date of the grant.

## NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the six months ended 30 June 2025

### 21. SHARE-BASED PAYMENT TRANSACTIONS - CONTINUED

#### (B) SHARE AWARD SCHEME - CONTINUED

##### *EQUITY-SETTLED SHARE AWARD SCHEME OF THE COMPANY - CONTINUED*

The following table discloses movements of the 2022 Share Award Scheme during the six months ended 30 June 2025 and 2024:

	Six months ended 30 June	
	2025 Number of shares	2024 Number of shares
Unvested at the beginning of the period	15,615,000	18,650,000
Granted during the period	81,346,000	—
Vested during the period	(83,618,500)	(1,690,000)
Lapsed during the period	(255,000)	(665,000)
Unvested as at the end of the period	13,087,500	16,295,000

The fair value of the granted shares was based on the closing price of the shares on the grant date.

For the six months ended 30 June 2025, the Group recognised approximately RMB156,091,000 (corresponding period of 2024: approximately RMB5,356,000) share-based payment expenses in profit or loss in relation to the 2022 Share Award Scheme. In addition, approximately RMB456,000 (corresponding period of 2024: approximately RMB303,000) was capitalised in development costs.

#### (C) RESTRICTED SHARE SCHEME

On 5 January 2023, Lifetech Shenzhen adopted a Restricted Share Scheme ("2023 Restricted Share Scheme"). The purpose of the 2023 Restricted Share Scheme is (i) to recognise and motivate the contributions by certain eligible participants and to incentivise them and retain them for the continual operation and development of the Group; (ii) to attract suitable personnel for further development of the Group; and (iii) to provide certain eligible participants with a direct economic interest in attaining a long-term relationship between the Group and certain eligible participants.

In 2023, a total of 4,417,500 shares of Biotyx Medical held on behalf of Lifetech Shenzhen have been granted by Lifetech Shenzhen to certain employees at price of RMB1.00 and the vesting period under the 2023 Restricted Share Scheme ranges from five years to six years.



## NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the six months ended 30 June 2025

### 21. SHARE-BASED PAYMENT TRANSACTIONS - CONTINUED

#### (C) RESTRICTED SHARE SCHEME - CONTINUED

The following table discloses movements of the 2023 Restricted Share Scheme during the six months ended 30 June 2025:

	Outstanding as at 30 June 2025
Shares granted on 5 January 2023:	4,417,500

The fair value of shares granted was based on the recent transaction price of the shares.

For the six months ended 30 June 2025, the Group recognised approximately RMB3,697,000 (corresponding period of 2024: approximately RMB3,758,000) share-based payment expenses in profit or loss in relation to the 2023 Restricted Share Scheme. In addition, approximately RMB318,000 (corresponding period of 2024: approximately RMB257,000) was capitalised in development costs.

#### (D) EQUITY-SETTLED SHARE-BASED PAYMENT EXPENSES RECOGNISED IN THE CONSOLIDATED STATEMENT OF PROFIT OR LOSS

	Six months ended 30 June	
	2025 RMB'000 (Unaudited)	2024 RMB'000 (Unaudited)
Cost of sales	1,577	1,990
Research and development expenses	8,922	19,212
Administration expenses	54,635	16,044
Selling and distribution expenses	128,366	24,079
	193,500	61,325

## NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the six months ended 30 June 2025

### 22. OPERATING LEASES

#### THE GROUP AS LESSOR

All of the investment properties held by the Group for rental purpose have committed leases for the next 1 to 10 years.

Undiscounted lease payments receivable on leases are as follows:

	30 June 2025 RMB'000 (Unaudited)	31 December 2024 RMB'000 (Audited)
Within one year	35,505	38,895
In the second year	26,290	34,772
In the third year	17,518	26,080
In the fourth year	12,461	19,090
In the fifth year	9,808	15,841
Over five years	8,437	14,077
	<b>110,019</b>	<b>148,755</b>

### 23. CAPITAL COMMITMENTS

	30 June 2025 RMB'000 (Unaudited)	31 December 2024 RMB'000 (Audited)
Capital expenditure in respect of acquisition of property, plant and equipment - contracted for but not provided in the condensed consolidated financial statements	<b>46,307</b>	<b>55,097</b>

## NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the six months ended 30 June 2025

### 24. RELATED PARTY DISCLOSURES

#### [A] SIGNIFICANT RELATED PARTY TRANSACTION

The Group entered into the following transactions with the related party during the six months ended 30 June 2025 and 2024.

		Six months ended 30 June	
Relationships	Nature of transactions	2025 RMB'000 (Unaudited)	2024 RMB'000 (Unaudited)
Associate	Consulting services	8,260	4,634
	Equipment leasing	563	563
		8,823	5,197

#### [B] COMPENSATION OF KEY MANAGEMENT PERSONNEL

The remuneration of key management personnel during the period was as follows:

	Six months ended 30 June	
Nature of transactions	2025 RMB'000 (Unaudited)	2024 RMB'000 (Unaudited)
Short-term employee benefits	14,937	12,861
Post-employment benefits	189	119
	15,126	12,980

The remuneration of key management personnel is determined by reference to the performance of individuals and market trends.